

LEGISLATIVE APPROPRIATIONS REQUEST

FISCAL YEARS 2024 AND 2025



Submitted to the Governor's Office
and the Legislative Budget Board

THE UNIVERSITY OF TEXAS
M. D. ANDERSON CANCER CENTER

August 2022

TABLE OF CONTENTS

ADMINISTRATOR'S STATEMENT	Pages 1 - 9
ORGANIZATIONAL CHART	1.B. Pages 1-1
BUDGET OVERVIEW – BIENNIAL AMOUNTS.....	Pages 1-1
SUMMARY OF BASE REQUEST BY STRATEGY	2.A. Pages 1-5
SUMMARY OF BASE REQUEST BY METHOD OF FINANCE	2.B. Pages 1-9
SUMMARY OF BASE REQUEST BY OBJECT OF EXPENSE	2.C. Page 1-1
SUMMARY OF BASE REQUEST OBJECTIVE OUTCOMES.....	2.D. Page 1-1
SUMMARY OF EXCEPTIONAL ITEM REQUEST	2.E. Page 1-1
SUMMARY OF TOTAL REQUEST BY STRATEGY	2.F.Pages 1-3
SUMMARY OF TOTAL REQUEST OBJECTIVE OUTCOMES	2.G. Pages 1-2
STRATEGY REQUESTS:	3.A. Pages 1-31
Allied Health Professions Training.....	1-3
Graduate Medical Education.....	4-5
Cancer Center Operations	6-8
Staff Group Insurance.....	9-10
Texas Public Education Grants	11-12
Research Enhancement.....	13-14

STRATEGY REQUESTS (continued):

E&G Space Support	15-17
Capital Construction Assistance Projects Revenue Bond	18-20
Cord Blood and Cellular Therapy Research Program	21-22
Breast Cancer Research Program	23-24
Institutional Enhancement	25-26
Tobacco Earnings for the UT M. D. Anderson Cancer Center	27-28
Tobacco Earnings from the Permanent Health Fund for Higher Education No. 810.....	29-30
Strategy Request Summary Totals	30

RIDER REVISIONS AND ADDITIONS REQUEST.....3.B. Page 1-2

EXCEPTIONAL ITEM REQUEST SCHEDULES:

Exceptional Item Request Schedule	4.A. Page 1-4
Exceptional Item Strategy Allocation Schedule	4.B. Page 1-2
Exceptional Items Strategy Request.....	4.C. Page 1-2

SUPPORTING SCHEDULES:

Historically Underutilized Business Supporting Schedule	6.A Page 1-2
Estimated Funds Outside the GAA	6.H.

HIGHER EDUCATION SUPPORTING SCHEDULES:

Schedule 1A - Other Educational and General Income	1-3
Schedule 1B - Health-related Institutions Patient Income	1
Schedule 2 – Selected Educational, General, and Other Funds	1
Schedule 3B - Staff Group Insurance Data Elements (UT/A&M)	1-3
Schedule 4 - Computation of OASI	1
Schedule 5 - Calculation of Retirement Proportionality and ORP Differential	1
Schedule 6 - Capital Funding	1
Schedule 7 - Personnel	1
Schedule 8B – CCAP Revenue Bond Issuance History	1
Schedule 8C – CCAP Revenue Bond Debt Service Requests by Project	Pages 1-1
Schedule 9 – Non-Formula Support Information	Pages 1-7
Cord Blood & Cellular Therapy Research Program	1-2
Inflammatory Breast Cancer (IBC) Research Program	3-5
Institutional Enhancement	6-7

Schedules Not Included

Agency Code: 506	Agency Name: The University of Texas M. D. Anderson Cancer Center.	Prepared By: Tomas Guajardo	Date: August 2022	Request Level: Baseline
For the schedules identified below, the U. T. M. D. Anderson Cancer Center either has no information to report or the schedule is not applicable. Accordingly, these schedules have been excluded from the U. T. M. D. Anderson Cancer Center Legislative Appropriations Request for the 2024-25 biennium.				
Number	Name			
2.C.1.	Operating Costs Detail – Base Request			
3.C.	Rider Appropriations and Unexpended Balances Request			
5.A – 5.E	Capital Budget Supporting Schedules			
6.B.	Current Biennium One-time Expenditure Schedule			
6.C-6.D	Federal Funds Supporting and Tracking Schedule			
6.E	Estimated Revenue Collections Supporting Schedule			
6.F.	Advisory Committee Supporting Schedule			
6.J.	Summary of Behavioral Health Funding (UTHSCH and UTHSCT Only along with any institution requesting this funding in an exceptional item)			
6.K	Budgetary Impacts Related to Recently Enacted State Legislation Schedule			
7.A.	Indirect Administrative and Support Costs			
7.B.	Direct Administrative and Support Costs			
8.	Summary of Requests for Capital Project Financing			
Schedule 3A	Staff Group Insurance Data Elements (ERS)			
Schedule 3D	Staff Group Insurance Elements – Supplemental (UTMB, UTHSCH, TTUHSC and Texas Forest Service)			
Schedule 8A	Proposed CCAP Revenue Bond Schedule			

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center was created by the Texas Legislature in 1941 as a component of The University of Texas System. MD Anderson is one of the nation's original three Comprehensive Cancer Centers designated by the National Cancer Act of 1971 and is one of 52 Comprehensive Cancer Centers today.

U.S. News & World Report's "America's Best Hospitals" survey ranked MD Anderson as the top hospital in the nation for cancer care for 2021-22. The institution has ranked as one of the top two hospitals for cancer care since the magazine began its annual survey in 1990.

MD Anderson's mission is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention and through education for undergraduate, graduate students, trainees, professionals, employees and the public.

Magnitude of the Cancer Problem

Cancer is the second most common cause of death in the United States. While cancer strikes at any age, 80% of all cancers occur in people age 55 and older. Over 139,300 Texans are estimated to be newly diagnosed with cancer in 2022 and approximately 43,500 Texans are estimated to die of the disease this year.

According to the American Cancer Society, as of January 2019, an estimated 16.9 million Americans are living with a history of surviving cancer. The five-year survival rate for all forms of cancer combined has risen to 68%, up from 49% in the 1970's, meaning more Americans are living with a history of cancer and require medical follow-up. Those not cured are living longer as a result of earlier detection and improved therapies, but they require more medical resources.

Institutional Strategy

In 2021, MD Anderson launched a pivotal, multi-year strategy aimed at making the greatest impact on humanity in the institution's work to end cancer. Developed with direct involvement from front-line cancer fighters and through ideas curated from faculty, MD Anderson's new Strategy is anchored in its mission and grounded in its unwavering commitment to our stakeholders.

The strategy aligns the institution and its resources around three strategic themes: Reach, Breakthroughs and Value. Coupled with a purposefully designed execution framework, the Strategy will drive cancer care that is more accessible in the communities that MD Anderson serves, develop high-impact research that improves people's health, and both define and deliver high-value oncology care. The strategic themes also will support signature philanthropy priorities that have been deliberately linked to MD Anderson's new Strategy.

Each theme contains a series of underlying strategic decisions and actions grounded in the same aspirational principle: to make the greatest impact on humanity to finally end cancer. The aims of each theme:

Reach

Make it easier for the patients and communities we serve to access our expertise to ultimately prevent disease and improve health.

- Physical
 - o We will expand our geographic footprint in Texas.

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

- o We will develop a best-in-class inbound international patient program.
- Virtual
 - o We will increase access to our services by expanding our virtual presence and capabilities.
 - o We will become the nation's leading health care digital resource for cancer information.
- Partnerships
 - o We will build strategic partnerships with other providers to promote prevention and screening services in community settings and by transitioning appropriate patients for survivorship and end-of-life care.
 - o We will redefine the MD Anderson Cancer Network® offerings to create a single partnership model, a nationwide network of high-quality cancer centers that can be offered to employers and payors, giving their employees and members access to MD Anderson-level care and clinical trials closer to home.
 - o We will refocus our international programming model to develop organization-to-government and non-governmental organization relationships.

Breakthroughs

Drive high-impact discovery research focused on unmet medical need and accelerate translation into meaningful improvements in health outcomes to become the No. 1 cancer research organization.

- Impact
 - o We will build a world-class data science program in oncology through internal alignment, investment, and academic and industry partnerships.
 - o We will seamlessly connect basic, translational and clinical research, and leverage unique insights from our large-scale clinical enterprise and patients to rapidly change patient outcomes and transform cancer care.
- Accessibility
 - o We will accelerate and expand our clinical trials efforts by establishing a transparent data-driven evaluation process that prioritizes trials with the greatest impact. We will scale our research efforts by building a national clinical trials network.
 - o We will foster meaningful state, national and international research collaborations through alliances with both academic and industry partners.
 - o We will align our research with our mission by engaging a broader segment of the Texas population in our research, emphasizing diverse populations, the underserved and areas of unmet clinical need.
- Culture
 - o We will invest in research excellence, talent, and the academic mission by enhancing the recruitment and retention of outstanding and diverse researchers, promoting both individual scientific excellence and team science, and emphasizing and rewarding ethical behaviors and professionalism.
 - o We will develop innovative education and training programs to prepare a future workforce to transform cancer care and research.
 - o We will enhance research infrastructure and drive institutional research stewardship by supporting objective, data-driven, benchmarked mechanisms for institutional funding, research space allocation and stewardship of resources.

Value

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Set new standards for high-touch, high-value cancer care.

- Quality
 - o We will invest in programs and services that enable us to see more early stage cancer patients, on whom we have the greatest impact. We will use cost, quality and outcome data to standardize care for these patients.
 - o We will establish and meet a targeted range for our performance in Vizient's national oncology rankings and we will evolve our operations, clinical practice and policies to reach it.
- Experience
 - o We will retain more patients for enrollment in clinical trials and to benefit from our multidisciplinary team-based care.
 - o We will optimize patient experience via a comprehensive navigation program and improved care transitions.
 - o We will transform clinical care by deeply integrating goal-concordant care through the adoption of empathetic pathways to patient preference that begin in the ambulatory setting.
- Cost
 - o We will enhance our focus on operational excellence, including inpatient throughput, weekend clinical operations and expanded hours where appropriate in order to enhance patient convenience and maximize our use of limited resources.
 - o We will proactively explore new reimbursement models.
 - o We will diversify our revenue streams by capitalizing on our knowledge and unique capabilities in collaboration with industry partners.

MISSION OVERVIEW

Patient Care

Since 1944, more than 1.8 million patients have turned to MD Anderson for cancer care in the form of targeted therapy, surgery, chemotherapy, radiation therapy, immunotherapy or combinations of these and other treatments. MD Anderson pioneered the multidisciplinary approach to treating cancer, bringing together teams of experts across disciplines to collaborate on the best treatment plan for patients. MD Anderson experts focus solely on cancer and are renowned for treating all types, including rare or uncommon diseases.

In FY 2021, more than 174,126 patients sought care at MD Anderson and over 41,000 of them were new patients. Over 9,700 registrants participated in therapeutic clinical research exploring novel treatments, the largest such cancer program in the nation.

The institution is accredited by the Joint Commission, an organization that ensures patients receive the best and safest health care possible. MD Anderson is among a select group of hospitals nationwide who have earned five consecutive Magnet Recognition Program® designations from the American Nurses Credentialing Center. This designation recognizes exceptional professional nursing staff and the ways their practice translates into excellent patient care and quality outcomes.

A significant challenge for MD Anderson is managing growth amid increasing patient demand. The institution must balance the number of patients with the resources

506 The University of Texas M.D. Anderson Cancer Center

available to care for them while accounting for the rising costs of health care. As with all healthcare institutions, MD Anderson faces strong pressures as reimbursements from state and federal programs decline, and commercial and managed care carriers negotiate coverage limits for certain services and payment rates. In FY2021, MD Anderson provided more than \$314 million in uncompensated care to uninsured and underinsured patients.

The Legislature provides funding to support MD Anderson's primary mission of patient care. It established the Cancer Center Operations Formula designed to support the institution's growth in patient care the same way that the current Health-Related Institutions (HRI) Instruction and Operations (I&O) Formula supports student growth for HRIs. Based on Texas cancer patients served each year, the maximum increase in the Operations Formula cannot exceed the average increase in the I&O Formula for all HRIs. Sustaining this critical support which recognizes MD Anderson's unique mission is the institution's highest budget priority.

Research

Important scientific knowledge gained in the laboratory is rapidly translated into clinical care at MD Anderson. Our research program is considered one of the most productive efforts in the world aimed solely at cancer. In FY 2021, the institution invested more than \$ 1.2 billion in research. Research support comes from a variety of sources: general revenue (GR) and tobacco funds (\$29 M); private industries (\$212 M); philanthropy (\$170 M); institutional funds (\$353 M); federal grants and contracts (\$217 M); and CPRIT (\$46 M).

MD Anderson continues to be a leader among its peers in the number of grants awarded and total amount of grant funding from the National Cancer Institute. The institution leads the nation in Specialized Programs of Research Excellence grants in the nation with its eight programs in brain, endometrial, gastrointestinal, hepatocellular, leukemia, melanoma, ovarian, and prostate cancers. A leader in accelerating progress and increasing access to novel agents for patients, MD Anderson ranks among the top institutions nationwide in revenue derived from IP-related agreements and corporate strategic research alliances. MD Anderson boasts one of the largest and most effective clinical trials programs in the nation, which gives our oncologists years of experience with cancer treatments before the Food and Drug Administration approves them.

The Institute for Applied Cancer Science continues to expand research and drug development capabilities. The Institute conducts stringent validation of new cancer targets, generates lead clinical compounds against those targets, and converts this deep scientific knowledge and sophisticated drug development activities into innovative clinical trials. The goal is to overcome an astounding 95% failure rate in cancer drug development.

The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy is an international center of clinical excellence focusing on using the latest advances in genetic information to develop safer, more effective treatments for patients on a case-by-case basis, commonly called precision medicine.

Significant Research Accomplishments

In order to advance our mission to eliminate cancer in Texas, the national and the world, MD Anderson researchers lead cutting edge science across the spectrum of cancer, including discovery, translational, clinical and prevention research. In the past 18 months, our scientists have published more than 60 studies in the highest profile journals, including Science, Cell, Nature and The New England Journal of Medicine. In FY 2021, 29 drugs evaluated in clinical trials at MD Anderson received FDA approval. Examples of impactful research include:

Ductal carcinoma in situ (DCIS) — abnormal cells inside the breast — is harmless for most women but can develop into invasive breast cancers in others. It's hard to

506 The University of Texas M.D. Anderson Cancer Center

predict which cases will advance, so most women diagnosed with DCIS will receive treatment that ultimately will provide little benefit. As part of the global Cancer Grand Challenges PRECISION team, MD Anderson researchers are working to better understand DCIS biology and identify the cases most likely to progress. In a new study published in Nature Genetics, they made discoveries that challenge a long-held belief about DCIS: that all cases of cancer following DCIS develop from the DCIS. Instead, they discovered that nearly 20% of cancers were not genetically related to the DCIS, meaning they are new cancers. This study provides key insights into the development of breast cancer and explains why it has been challenging to predict DCIS progression.

Mutant forms of the KRAS gene are the most common cancer drivers in lung cancer, found in 25-30% of patients, and several other cancer types. Until recently, there was little success in attempts to block mutant KRAS with targeted therapies. MD Anderson was pivotal in advancing the clinical development for sotorasib, which became the first-ever FDA approved KRAS inhibitor in 2021. Our clinicians led both the initial Phase I studies as well as the pivotal Phase II study that led to drug approval. The results of the Phase II trial, sotorasib, in 2021. The trial results, published in the New England Journal of Medicine, found that 80% of patients saw their tumors shrink or remain stable, including several that had tumors disappear. The drug also offered lasting benefits to patients that previously had no effective treatment options. MD Anderson continues to push the field forward, leading additional clinical trials with next-generation KRAS inhibitors that may offer improved responses or target unique mutations.

Moon Shots Program™

In 2012, MD Anderson embarked on a comprehensive effort to accelerate the pace of converting scientific discoveries into clinical advances and significantly reduce cancer-related mortality and suffering over the next decade. Cancer science has reached a point of conceptual and technological maturity, positioning the field to accelerate and systemize this effort. This program brings together teams of researchers and clinicians to mount comprehensive attacks on major cancers. They work as part of thirteen disease-focused initiatives and ten platforms to support the program's team-science approach and accelerate the translation of data and discoveries for patients' benefit. The program has received \$484.7 million in private philanthropic commitments and has attracted new grants and contracts in excess of \$668 million. The goal is for all cancers to become moon shot efforts.

The James P. Allison Institute & The Institute for Data Science in Oncology

MD Anderson launched the James P. Allison Institute, a visionary research and innovation hub within MD Anderson designed to foster groundbreaking science, to develop new treatments and to bring the benefits of immunotherapy to all patients.

The Allison Institute will advance exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.

The new Institute for Data Science in Oncology will unlock the power of data and enable impactful change through data science by: using intelligent systems to improve cancer patient safety and quality; streamlining operations to enable continuous monitoring and modeling of operational performance to enhance patient access and scheduling; and predicting outcomes for patients by finding optimal combinations of current and emerging treatments.

Education

506 The University of Texas M.D. Anderson Cancer Center

In FY 2021, nearly 4,800 trainees took part in educational programs, including physicians, scientists, nurses and many health professionals. MD Anderson offers degrees in ten bachelor's programs and two master's programs in allied health disciplines in its School of Health Professions, educating 377 students. Notably, 90% of surveyed graduates stayed to work in Texas hospitals and diagnostic labs. This is a critical need area as the demand for allied health professionals increases.

While MD Anderson is proud to fulfill its education mission, the institution must rely on institutionally-generated funds and grants to cover most of the costs of its education programs because of the small number of students that qualify for support under the HRI formulas.

More than 1,680 clinical residents and fellows come to MD Anderson each year to receive specialized training in the investigation and treatment of cancer. Over 350 graduate students are working on advanced degrees at the Graduate School of Biomedical Sciences, which MD Anderson operates jointly with UT Health. In addition, over 1,360 research trainees are taught in MD Anderson's laboratories. Accreditation by the Commission on Colleges of the Southern Association of Colleges and Schools affirms MD Anderson as a major teaching institution, recognizing the faculty for their influential role in educating graduate and undergraduate students.

Prevention

MD Anderson continues to set the standard in cancer prevention research and the translation of new knowledge into innovative, multidisciplinary care for patients, survivors and people at average or elevated risk of developing cancer. The Division of Cancer Prevention and Population Sciences is dedicated to eradicating cancer through pioneering research in the roles that biologic, genetic, environmental, behavioral and social factors play in cancer development and investigations of behavioral, surgical, medical and social interventions to prevent or reduce cancer risk.

In the context of the Moon Shots™ effort, the institution is increasingly focused on cancer prevention and control programs in policy, education (public and professional) and services in the community through the Cancer Prevention and Control Platform. The Platform is keenly focused on developing and implementing evidence-based interventions in cancer prevention, screening, early detection and survivorship, to achieve a measurable and lasting reduction in the cancer burden. A significant focus is the impact of tobacco-related illnesses. The use of tobacco is one of the greatest public health menaces of our time, driving approximately 30% of all cancer deaths in the United States. This year, almost 500,000 Americans and 7 million people worldwide will die from tobacco-related illnesses.

Motivated by the daily suffering that we witness by patients and their families, a cross-functional team delivered a comprehensive program, called EndTobacco™, that recommends strategic and tactical actions in the areas of policy, education and community-based services that MD Anderson can take to address the tobacco burden within the institution and beyond in organizations and communities across the state, the nation, and the world. EndTobacco™ is founded on best practices in tobacco control as established by the Centers for Disease Control and Prevention and the World Health Organization.

Human Resources and Facilities

MD Anderson employs nearly 23,000 people, including more than 1,800 faculty. MD Anderson was ranked No. 10 on Forbes' "America's Best Large Employers for 2022." MD Anderson also was included in Forbes' 2022 ranking of "Best Employers for Diversity;" as well as, "The Best Employer for New Grads." The institution was also recognized by the Military Times as a 2021 Best for Vets employer. Additionally, MD Anderson earned a top score of 100% on the 2021 Disability Equality Index, the nation's most comprehensive annual benchmarking tool, and ranked number 19 by Glassdoor.com on their 2021 list of the nation's best large places to work.

MD Anderson is the largest freestanding cancer center in the world. Facilities in the Texas Medical Center (TMC) cover more than 15 million square feet and feature the latest equipment and infrastructure to support growing needs in outpatient and inpatient care, research, prevention and education.

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

The Keeling Center for Comparative Medicine and Research, located on 375 acres near the City of Bastrop, houses chimpanzees, rhesus monkeys, sheep, cattle, swine, chickens and rodents, and has an international reputation for innovation in breeding and managing many species vital to biomedical research at MD Anderson and all over the U.S. More than 100 personnel, including veterinarians, animal handlers, research technicians and administrative staff conduct research in cancer, HIV, hepatitis, obesity and vaccine development. The campus has earned an international reputation for laboratory animal science and comparative medicine as well as housing, care and re-socializing of chimpanzees.

The TMC3 initiative is a vision to enhance collaboration, innovation, translation and commercialization in the Texas Medical Center. The collaborative and commercialization life sciences potential of Houston is underleveraged when compared to smaller cities with fewer institutions and less philanthropic and National Institutes of Health funding. Founding institutions are UT Health, UT MD Anderson Cancer Center, Texas A&M University System and the Texas Medical Center, Inc.

Development of the translational research campus on TMC-owned and UT System-owned land in the TMC Mid-Campus and UT System Research Park is underway. The campus components include: four research buildings; collaborative space; shared core labs, office, meeting/conference/education space; building sites for industry; and parking. UT System institutions are building research facilities located in the UT Research Park, and focused on leveraging 2,000 investigators, staff and industry collaborators present in the UT Research Park, with a planned bridge connecting the South Campus to the TMC Mid-campus.

MD Anderson received \$70 million in Capital Construction Assistance Projects (CCAP) revenue bond support last session for its dedicated research facility in the innovation hub. If the state considers CCAPs in the 88th Texas Legislature, we respectfully request additional support for this project.

MD Anderson has developed local care sites as well as national and international partnerships to deliver its high-quality cancer care outside of the main campus. Houston Area Locations are in communities throughout the greater Houston area.

Houston Area Locations

Greater Houston: League City, West Houston, Sugar Land, The Woodlands, The Woman's Hospital of Texas (Gynecologic Oncology Clinic), Harris Health System's Lyndon B. Johnson Hospital (MD Anderson Oncology Program)

Cancer Network - Partner Members

Banner MD Anderson Cancer Center (Gilbert, AZ); MD Anderson Cancer Center at Cooper (Camden, NJ); Baptist MD Anderson Cancer Center (Jacksonville, FL); Scripps MD Anderson Cancer Center (San Diego, CA); UT Health San Antonio; Community Health Network MD Anderson Cancer Center (Indianapolis, IN)

Cancer Network - Certified Members

AdventHealth Cancer Center (Kansas City, KS); Centura Health (Colorado Springs, CO & Pueblo, CO); Covenant Healthcare (Saginaw, MI); DCH Regional Medical Center (Tuscaloosa, AL); Deaconess Health System (Evansville, IN); Frederick Health (Frederick, MD); OhioHealth (Columbus, OH); Premier Health (Dayton, OH); Presbyterian Healthcare Services (Albuquerque, NM); The Queen's Medical Center (Honolulu, HI)

Cancer Network - Associate Members

MD Anderson Cancer Center Madrid (Spain)

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

SIGNIFICANT ACHIEVEMENTS

MD Anderson's faculty is one of the most esteemed in the nation, including one Nobel Laureate, eight members of the National Academy of Medicine, six National Academy of Sciences members, six American Academy of Arts and Sciences members and 48 American Association for the Advancement of Science fellows, twelve Association of American Physician members and 27 American Society of Clinical Investigation members.

The HUB & Federal Small Business Program was recognized for supplier diversity excellence in FY2020 with several accolades. The HUB Program Associate Director was awarded the connector Award for outstanding performance in connecting with Small diverse businesses by the Greater Houston Procurement Forum. MD Anderson received from the Houston Minority Supplier Development Council (HSMDC) "the Corporation of the Year" award for demonstrating the highest level of contributing efforts to support MBEs and received from The Women Business Enterprise Alliance (WBEA) the Cutting Edge Award for given outstanding growth and utilization of WBE's. Also, the HUB Program was published in Premier Inc.'s "Supplier Diversity in Healthcare" 2020 whitepaper. In FY 2021, MD Anderson created the first comprehensive MD Anderson HUB Contractor Guide designed to provide HUB Contractors with a book of knowledge on the entire procurement process and how to be successful.

STATE SUPPORT

General Revenue

The GR appropriation, \$205 million in FY 2022, accounted for 3.5% of the total operating budgeted revenues prior to the COVID-19 pandemic, providing critical support for patient care, education, research and infrastructure. The FY 2024-25 request is at 100% of base FY 2022-23 funding with the exception of debt service. MD Anderson maximizes its leveraging of state funding. In FY 2021, the institution generated \$35.2 additional dollars for cancer patient care, education and research for each \$1 of GR; and \$44.4 in research support for every \$1 of GR from the state for research, illustrating a sound investment for Texas.

Tobacco Settlement Funds

The Legislature established a permanent \$100 million endowment for MD Anderson in 1999. The fund provided \$6.7 million in FY 2020 for tobacco-related research programs. A separate endowment for all HRIs provided \$2.5 million for these purposes. The following programs received settlement funds in FY 2020: \$5.5 million for Cancer Prevention, including: Tobacco Treatment Program; Tobacco Outreach Education Program; Tobacco Faculty Support; Tobacco Trainee and Junior Faculty Program, and Tobacco Disparities and Fellows Program; Mexican American Cohort; Patient History Database and Population Sciences Laboratory Resource Center. It also provides \$0.9 million for Molecular Mechanisms Tobacco Carcinogenesis and \$2.3 million for Research Equipment.

Required Statement on Criminal History

MD Anderson's policy is to obtain state criminal history information on non-faculty finalists considered for appointment to a security sensitive position and national data on faculty candidates, as allowed by Government Code Sec. 411.094 and Education Code Sec. 51.215. All positions are designated as security-sensitive. Criminal background information may not be released or disclosed to any unauthorized person, except on court order.

EXCEPTIONAL ITEMS

Administrator's Statement

7/27/2022 2:44:00PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

1) Increase for the Cord Blood & Cellular Therapy Research Program

MD Anderson is the world leader in stem cell transplantation. Prior to the budget reductions for FY 2012-13, the MD Anderson Cord Blood Bank received funding from the Legislature through the Texas Health and Human Services Commission. GR support was instrumental in advancing the field of cord blood transplantation and these funds were leveraged to generate in excess of \$12 million external funding for the program.


Funding currently supports the Cord Blood Bank and Good Manufacturing Laboratory (GMP) with the development and management of critical research protocols for cord blood transplantation and other cellular therapies, including rapid and exciting developments of chimeric antigen receptor (CAR) T cell therapy and CAR natural killer (NK) cell treatments for hematologic and solid tumors. These novel therapeutic approaches harness the body's own immune system to effectively fight cancers by killing abnormal cells. Cord blood provides a source of stem cells for transplant for minority patients who often have no registered donors. MD Anderson serves an unmet need as 75% of the cord blood units in the bank are of Hispanic origin and the institution finds units for patients that otherwise would not have donors.

2) Restoration for the Rare and Aggressive Breast Cancer Research Program

Program funding was reduced in 2013 and 2017. This request fully restores funding reductions and provides a modest increase for the Inflammatory Breast Cancer (IBC) Research Program and Clinic. IBC is an aggressive, often fatal, type of breast cancer that is commonly misdiagnosed. Through the legislature's investment, more patients with IBC are seen at MD Anderson than any other center in the world. State funding provided for: development of the world's largest bio-repository of tissue and serum samples from our IBC patients; and partnership with other centers around the world to expand the repository, accelerate development of new therapies, and ultimately improve the well-being of all women who suffer from this commonly misdiagnosed disease.

1.B. ORGANIZATIONAL CHART

All Funds FTEs for
6/1/2022: 21,986



*These functions have an administrative reporting relationship to the SVP/Chief and a functioning reporting relationship to the President.

Budget Overview - Biennial Amounts
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center
Appropriation Years: 2024-25

	GENERAL REVENUE FUNDS		GR DEDICATED		FEDERAL FUNDS		OTHER FUNDS		ALL FUNDS		EXCEPTIONAL ITEM FUNDS
	2022-23	2024-25	2022-23	2024-25	2022-23	2024-25	2022-23	2024-25	2022-23	2024-25	2024-25
Goal: 1. Provide Instructional and Operations Support											
1.1.1. Allied Health Professions Training	6,408,806		320,000						6,728,806		
1.1.2. Graduate Medical Education	1,779,024								1,779,024		
1.2.1. Cancer Center Operations	280,815,980								280,815,980		
1.3.1. Staff Group Insurance Premiums			53,171	54,055					53,171	54,055	
1.4.1. Texas Public Education Grants			213,840	224,666					213,840	224,666	
Total, Goal	289,003,810		587,011	278,721					289,590,821	278,721	
Goal: 2. Provide Research Support											
2.1.1. Research Enhancement	25,413,576								25,413,576		
Total, Goal	25,413,576								25,413,576		
Goal: 3. Provide Infrastructure Support											
3.1.1. E&G Space Support	68,144,344		1,062,325						69,206,669		
3.2.1. Ccap Revenue Bonds	22,655,000	34,816,748							22,655,000	34,816,748	
Total, Goal	90,799,344	34,816,748	1,062,325						91,861,669	34,816,748	
Goal: 5. Provide Non-formula Support											
5.1.1. Cord Blood And Cellular Therapy	2,779,102	2,779,101							2,779,102	2,779,101	1,220,899
5.1.2. Breast Cancer Research Program	2,888,000	2,888,000							2,888,000	2,888,000	1,112,000
5.2.1. Institutional Enhancement							9,061	4,328	9,061	4,328	
Total, Goal	5,667,102	5,667,101					9,061	4,328	5,676,163	5,671,429	2,332,899
Goal: 7. Tobacco Funds											
7.1.1. Tobacco Earnings - Ut Md Anderson							14,125,550	13,780,000	14,125,550	13,780,000	
7.1.2. Tobacco - Permanent Health Fund							9,398,325	5,123,782	9,398,325	5,123,782	
Total, Goal							23,523,875	18,903,782	23,523,875	18,903,782	
Total, Agency	410,883,832	40,483,849	1,649,336	278,721			23,532,936	18,908,110	436,066,104	59,670,680	2,332,899
Total FTEs									617.1	617.1	0.0

506 The University of Texas M.D. Anderson Cancer Center

Goal / Objective / STRATEGY	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
1 Provide Instructional and Operations Support					
1 <i>Instructional Programs</i>					
1 ALLIED HEALTH PROFESSIONS TRAINING (1)	3,518,817	3,364,403	3,364,403	0	0
2 GRADUATE MEDICAL EDUCATION (1)	877,572	889,512	889,512	0	0
2 <i>Cancer Center Operations</i>					
1 CANCER CENTER OPERATIONS (1)	140,407,990	140,407,990	140,407,990	0	0
3 <i>Operations - Staff Benefits</i>					
1 STAFF GROUP INSURANCE PREMIUMS	26,725	26,936	26,235	26,760	27,295
4 <i>Operations - Statutory Funds</i>					
1 TEXAS PUBLIC EDUCATION GRANTS	95,986	105,600	108,240	110,946	113,720
TOTAL, GOAL 1	\$144,927,090	\$144,794,441	\$144,796,380	\$137,706	\$141,015

2 Provide Research Support**1** *Research Activities*

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

2.A. Summary of Base Request by Strategy

7/21/2022 1:50:40PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Goal / Objective / STRATEGY	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
1 RESEARCH ENHANCEMENT (1)	11,529,638	12,706,788	12,706,788	0	0
TOTAL, GOAL 2	\$11,529,638	\$12,706,788	\$12,706,788	\$0	\$0
3 Provide Infrastructure Support					
1 Operations and Maintenance					
1 E&G SPACE SUPPORT (1)	32,057,308	34,593,238	34,613,431	0	0
2 Infrastructure Support					
1 CCAP REVENUE BONDS	11,327,350	11,327,350	11,327,650	17,419,549	17,397,199
TOTAL, GOAL 3	\$43,384,658	\$45,920,588	\$45,941,081	\$17,419,549	\$17,397,199
5 Provide Non-formula Support					
1 Research					
1 CORD BLOOD AND CELLULAR THERAPY	1,100,914	1,389,551	1,389,551	1,389,551	1,389,550
2 BREAST CANCER RESEARCH PROGRAM	1,520,000	1,444,000	1,444,000	1,444,000	1,444,000
2 Institutional					

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

2.A. Summary of Base Request by Strategy

7/21/2022 1:50:40PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Goal / Objective / STRATEGY	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
1 INSTITUTIONAL ENHANCEMENT	361,772	4,397	4,664	2,164	2,164
TOTAL, GOAL 5	\$2,982,686	\$2,837,948	\$2,838,215	\$2,835,715	\$2,835,714
7 Tobacco Funds					
1 Tobacco Earnings for Research					
1 TOBACCO EARNINGS - UT MD ANDERSON	8,677,271	6,233,550	7,892,000	6,890,000	6,890,000
2 TOBACCO - PERMANENT HEALTH FUND	3,201,473	5,327,934	4,070,391	2,561,891	2,561,891
TOTAL, GOAL 7	\$11,878,744	\$11,561,484	\$11,962,391	\$9,451,891	\$9,451,891
TOTAL, AGENCY STRATEGY REQUEST	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819
TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST*				\$0	\$0
GRAND TOTAL, AGENCY REQUEST	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819

2.A. Summary of Base Request by Strategy

7/21/2022 1:50:40PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Goal / Objective / STRATEGY	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>METHOD OF FINANCING:</u>					
General Revenue Funds:					
1 General Revenue Fund	102,475,534	205,441,766	205,442,066	20,253,100	20,230,749
SUBTOTAL	\$102,475,534	\$205,441,766	\$205,442,066	\$20,253,100	\$20,230,749
General Revenue Dedicated Funds:					
704 Est Bd Authorized Tuition Inc	86,438	79,899	81,896	0	0
770 Est. Other Educational & General	644,472	733,703	753,838	137,706	141,015
SUBTOTAL	\$730,910	\$813,602	\$835,734	\$137,706	\$141,015
Federal Funds:					
325 Coronavirus Relief Fund	99,617,628	0	0	0	0
SUBTOTAL	\$99,617,628	\$0	\$0	\$0	\$0
Other Funds:					
802 Lic Plate Trust Fund No. 0802, est	0	4,397	4,664	2,164	2,164
810 Perm Health Fund Higher Ed, est	3,201,473	5,327,934	4,070,391	2,561,891	2,561,891
812 Perm Endow FD UTMD AND, estimated	8,677,271	6,233,550	7,892,000	6,890,000	6,890,000
SUBTOTAL	\$11,878,744	\$11,565,881	\$11,967,055	\$9,454,055	\$9,454,055
TOTAL, METHOD OF FINANCING	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819

*Rider appropriations for the historical years are included in the strategy amounts.

2.A. Summary of Base Request by Strategy

7/21/2022 1:50:40PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Goal / Objective / STRATEGY	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
------------------------------------	-----------------	-----------------	-----------------	-----------------	-----------------

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
METHOD OF FINANCING	Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025	
<u>GENERAL REVENUE</u>						
<u>1</u> General Revenue Fund						
REGULAR APPROPRIATIONS						
Regular Appropriations from MOF Table (2020-21 GAA)	\$202,093,162	\$0	\$0	\$0	\$0	
Regular Appropriations from MOF Table (2022-23 GAA)	\$0	\$199,935,897	\$199,936,197	\$0	\$0	
Regular Appropriations from MOF Table (2024-25 GAA)	\$0	\$0	\$0	\$20,253,100	\$20,230,749	
RIDER APPROPRIATION						
Art IX, Sec 17.47 Additional Funding for Formula Funding	\$0	\$5,505,869	\$5,505,869	\$0	\$0	
SUPPLEMENTAL, SPECIAL OR EMERGENCY APPROPRIATIONS						
87th Legislature, Regular Session, House Bill 2	\$(99,617,628)	\$0	\$0	\$0	\$0	
Comments: General Revenue savings as a result of OOG grant award from the Coronavirus Relief Fund to address expenses directly related to the agency's COVID-19 pandemic response.						

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 506		Agency name: The University of Texas M.D. Anderson Cancer Center				
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>GENERAL REVENUE</u>						
TOTAL, General Revenue Fund		\$102,475,534	\$205,441,766	\$205,442,066	\$20,253,100	\$20,230,749
TOTAL, ALL GENERAL REVENUE		\$102,475,534	\$205,441,766	\$205,442,066	\$20,253,100	\$20,230,749
<u>GENERAL REVENUE FUND - DEDICATED</u>						
<u>704</u> GR Dedicated - Estimated Board Authorized Tuition Increases Account No. 704						
<i>REGULAR APPROPRIATIONS</i>						
Regular Appropriations from MOF Table (2020-21 GAA)		\$69,750	\$0	\$0	\$0	\$0
Regular Appropriations from MOF Table (2022-23 GAA)		\$0	\$65,848	\$65,848	\$0	\$0
<i>BASE ADJUSTMENT</i>						
Revised Receipts		\$16,688	\$14,051	\$16,048	\$0	\$0
TOTAL, GR Dedicated - Estimated Board Authorized Tuition Increases Account No. 704		\$86,438	\$79,899	\$81,896	\$0	\$0
<u>770</u> GR Dedicated - Estimated Other Educational and General Income Account No. 770						

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>GENERAL REVENUE FUND - DEDICATED</u>						
<i>REGULAR APPROPRIATIONS</i>						
Regular Appropriations from MOF Table (2020-21 GAA)						
		\$703,095	\$0	\$0	\$0	\$0
Regular Appropriations from MOF Table (2022-23 GAA)						
		\$0	\$857,886	\$857,886	\$0	\$0
Regular Appropriations from MOF Table (2024-25 GAA)						
		\$0	\$0	\$0	\$137,706	\$141,015
<i>BASE ADJUSTMENT</i>						
Revised Receipts						
		\$(58,623)	\$(124,183)	\$(104,048)	\$0	\$0
TOTAL,	GR Dedicated - Estimated Other Educational and General Income Account No. 770	\$644,472	\$733,703	\$753,838	\$137,706	\$141,015
TOTAL GENERAL REVENUE FUND - DEDICATED - 704, 708 & 770						
		\$730,910	\$813,602	\$835,734	\$137,706	\$141,015
TOTAL, ALL	GENERAL REVENUE FUND - DEDICATED	\$730,910	\$813,602	\$835,734	\$137,706	\$141,015

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 506		Agency name: The University of Texas M.D. Anderson Cancer Center				
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
TOTAL,	GR & GR-DEDICATED FUNDS	\$103,206,444	\$206,255,368	\$206,277,800	\$20,390,806	\$20,371,764
<u>FEDERAL FUNDS</u>						
<u>325</u>	Coronavirus Relief Fund					
	<i>SUPPLEMENTAL, SPECIAL OR EMERGENCY APPROPRIATIONS</i>					
	87th Legislature, Regular Session, House Bill 2					
		\$99,617,628	\$0	\$0	\$0	\$0
	Comments: OOG grant award from the Coronavirus Relief Fund to address expenses directly related to the agency's COVID-19 pandemic response.					
TOTAL,	Coronavirus Relief Fund	\$99,617,628	\$0	\$0	\$0	\$0
TOTAL, ALL	FEDERAL FUNDS	\$99,617,628	\$0	\$0	\$0	\$0
<u>OTHER FUNDS</u>						
<u>802</u>	License Plate Trust Fund Account No. 0802, estimated					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2020-21 GAA)					
		\$2,164	\$0	\$0	\$0	\$0
	Regular Appropriations from MOF Table (2022-23 GAA)					

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>OTHER FUNDS</u>						
		\$0	\$2,164	\$2,164	\$0	\$0
	Regular Appropriations from MOF Table (2024-25 GAA)					
		\$0	\$0	\$0	\$2,164	\$2,164
<i>RIDER APPROPRIATION</i>						
	Art III, Special Provisions, Section 57 (2020-21 GAA)					
		\$3,019	\$0	\$0	\$0	\$0
	Art III, Special Provisions, Section 55 (2022-23 GAA)					
		\$(4,733)	\$4,733	\$0	\$0	\$0
	Art III, Special Provisions, Section 55 (2022-23 GAA)					
		\$0	\$(2,500)	\$2,500	\$0	\$0
<i>BASE ADJUSTMENT</i>						
	Revised Receipts					
		\$(450)	\$0	\$0	\$0	\$0
TOTAL,	License Plate Trust Fund Account No. 0802, estimated	\$0	\$4,397	\$4,664	\$2,164	\$2,164

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>OTHER FUNDS</u>						
<u>810</u>	Permanent Health Fund for Higher Education, estimated					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2020-21 GAA)					
		\$2,625,058	\$0	\$0	\$0	\$0
	Regular Appropriations from MOF Table (2022-23 GAA)					
		\$0	\$2,415,604	\$2,415,604	\$0	\$0
	Regular Appropriations from MOF Table (2024 - 25 GAA)					
		\$0	\$0	\$0	\$2,561,891	\$2,561,891
	<i>RIDER APPROPRIATION</i>					
	M.D. Anderson, Art III, Rider 5 UB Authority (2020-21 GAA)					
		\$5,122,123	\$0	\$0	\$0	\$0
	M.D. Anderson, Art III, Rider 5 UB Authority (2022-23 GAA)					
		\$(4,359,400)	\$4,359,400	\$0	\$0	\$0
	M.D. Anderson, Art III, Rider 5 UB Authority (2022-23 GAA)					
		\$0	\$(1,500,000)	\$1,500,000	\$0	\$0

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 506		Agency name: The University of Texas M.D. Anderson Cancer Center				
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>OTHER FUNDS</u>						
<i>BASE ADJUSTMENT</i>						
Revised Receipts - Distribution adjustment		\$(209,454)	\$44,255	\$146,287	\$0	\$0
Revised Receipts - Interest		\$23,146	\$8,675	\$8,500	\$0	\$0
TOTAL,	Permanent Health Fund for Higher Education, estimated	\$3,201,473	\$5,327,934	\$4,070,391	\$2,561,891	\$2,561,891
<u>812</u>	Permanent Endowment Fund, UT MD Anderson Cancer Center, estimated					
<i>REGULAR APPROPRIATIONS</i>						
Regular Appropriations from MOF Table (2020-21 GAA)		\$6,280,000	\$0	\$0	\$0	\$0
Regular Appropriations from MOF Table (2022-23 GAA)		\$0	\$6,550,000	\$6,550,000	\$0	\$0
Regular Appropriations from MOF Table (2024-25 GAA)		\$0	\$0	\$0	\$6,890,000	\$6,890,000

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 506		Agency name: The University of Texas M.D. Anderson Cancer Center				
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
<u>OTHER FUNDS</u>						
<i>RIDER APPROPRIATION</i>						
M.D. Anderson, Art III Rider 5 (2020-21 GAA)		\$2,679,260	\$0	\$0	\$0	\$0
M.D. Anderson, Art III Rider 5 (2022-23 GAA)		\$(561,401)	\$561,401	\$0	\$0	\$0
M.D. Anderson, Art III Rider 5 (2022-23 GAA)		\$0	\$(1,000,000)	\$1,000,000	\$0	\$0
<i>BASE ADJUSTMENT</i>						
Revised Receipts - Distributions		\$270,000	\$120,000	\$340,000	\$0	\$0
Revised Receipts - Interest		\$9,412	\$2,149	\$2,000	\$0	\$0
TOTAL,	Permanent Endowment Fund, UT MD Anderson Cancer Center, estimated	\$8,677,271	\$6,233,550	\$7,892,000	\$6,890,000	\$6,890,000
TOTAL, ALL	OTHER FUNDS	\$11,878,744	\$11,565,881	\$11,967,055	\$9,454,055	\$9,454,055

2.B. Summary of Base Request by Method of Finance

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
METHOD OF FINANCING		Exp 2021	Est 2022	Bud 2023	Req 2024	Req 2025
GRAND TOTAL		\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819
FULL-TIME-EQUIVALENT POSITIONS						
REGULAR APPROPRIATIONS						
Regular Appropriations from MOF Table (2020-21 GAA)		753.9	0.0	0.0	0.0	0.0
Regular Appropriations from MOF Table (2022-23 GAA)		0.0	757.9	757.9	0.0	0.0
Regular Appropriations from MOF Table (2024-25 GAA)		0.0	0.0	0.0	617.1	617.1
RIDER APPROPRIATION						
Art IX, Sec 17.47 - Additional Funding For Formula funding		0.0	44.0	44.0	0.0	0.0
UNAUTHORIZED NUMBER OVER (BELOW) CAP						
Unauthorized number over (below) the cap		(77.5)	(160.3)	(184.8)	0.0	0.0
TOTAL, ADJUSTED FTES		676.4	641.6	617.1	617.1	617.1
NUMBER OF 100% FEDERALLY FUNDED FTEs						

2.C. Summary of Base Request by Object of Expense

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)**506 The University of Texas M.D. Anderson Cancer Center**

OBJECT OF EXPENSE	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
1001 SALARIES AND WAGES	\$180,730,864	\$180,089,336	\$180,089,336	\$3,170,783	\$3,170,783
1002 OTHER PERSONNEL COSTS	\$1,243,409	\$934,042	\$933,341	\$819,889	\$820,424
1005 FACULTY SALARIES	\$9,820,985	\$12,203,003	\$12,203,003	\$1,122,617	\$1,122,617
2001 PROFESSIONAL FEES AND SERVICES	\$605,142	\$411,870	\$411,870	\$292,313	\$292,313
2003 CONSUMABLE SUPPLIES	\$392,274	\$410,999	\$410,999	\$109,559	\$109,559
2004 UTILITIES	\$3,212,427	\$3,842,976	\$3,854,419	\$1,494	\$1,494
2005 TRAVEL	\$0	\$86	\$86	\$54	\$54
2007 RENT - MACHINE AND OTHER	\$8,721	\$532	\$532	\$80	\$80
2008 DEBT SERVICE	\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
2009 OTHER OPERATING EXPENSE	\$4,575,509	\$1,867,018	\$3,458,373	\$2,873,395	\$2,873,394
4000 GRANTS	\$95,986	\$109,997	\$112,904	\$113,110	\$115,884
5000 CAPITAL EXPENDITURES	\$2,690,149	\$6,624,040	\$5,442,342	\$3,922,018	\$3,922,018
OOE Total (Excluding Riders)	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819
OOE Total (Riders)					
Grand Total	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819

2.D. Summary of Base Request Objective Outcomes

7/21/2022 1:50:41PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation system of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Goal/ Objective / Outcome	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
1 Provide Instructional and Operations Support					
1 Instructional Programs					
KEY 14 Percent Allied Health Grads Passing Certif/Licensure Exam First Try	92.00%	90.00%	90.00%	90.00%	90.00%
KEY 15 Percent Allied Health Graduates Licensed or Certified in Texas	100.00%	100.00%	100.00%	100.00%	100.00%
2 Cancer Center Operations					
KEY 1 Percent of Medical Residency Completers Practicing in Texas	34.00%	33.00%	33.00%	33.00%	33.00%
KEY 2 Total Uncompensated Care Provided by Faculty	91,664,661.00	91,664,661.00	91,664,661.00	91,664,661.00	91,664,661.00
KEY 4 Administrative (Instit Support) Cost As % of Total Expenditures	3.22%	3.50%	3.50%	3.50%	3.50%
KEY 5 Total Uncompensated Care Provided in State-owned Facilities	222,409,256.00	222,409,256.00	222,409,256.00	222,409,256.00	222,409,256.00
2 Provide Research Support					
1 Research Activities					
KEY 1 Total External Research Expenditures	628,776,864.00	638,208,517.00	647,781,645.00	657,498,369.00	667,360,845.00
2 External Research Expends As % of State Appropriations for Research	4,332.71%	4,397.70%	4,463.67%	4,530.62%	4,598.58%

2.E. Summary of Exceptional Items Request
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME : 1:50:41PM

Agency code: 506

Agency name: The University of Texas M.D. Anderson Cancer Center

Priority	Item	2024			2025			Biennium	
		GR and GR/GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds
1	Increases to Cord Blood	\$610,449	\$610,449		\$610,450	\$610,450		\$1,220,899	\$1,220,899
2	Increases to Breast Cancer Research	\$556,000	\$556,000		\$556,000	\$556,000		\$1,112,000	\$1,112,000
Total, Exceptional Items Request		\$1,166,449	\$1,166,449		\$1,166,450	\$1,166,450		\$2,332,899	\$2,332,899
Method of Financing									
	General Revenue	\$1,166,449	\$1,166,449		\$1,166,450	\$1,166,450		\$2,332,899	\$2,332,899
	General Revenue - Dedicated								
	Federal Funds								
	Other Funds								
		\$1,166,449	\$1,166,449		\$1,166,450	\$1,166,450		\$2,332,899	\$2,332,899

Full Time Equivalent Positions

Number of 100% Federally Funded FTEs

2.F. Summary of Total Request by Strategy
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE : 7/21/2022
TIME : 1:50:42PM

Agency code: 506 Agency name: The University of Texas M.D. Anderson Cancer Center

Goal/Objective/STRATEGY	Base 2024	Base 2025	Exceptional 2024	Exceptional 2025	Total Request 2024	Total Request 2025
1 Provide Instructional and Operations Support						
1 Instructional Programs						
1 ALLIED HEALTH PROFESSIONS TRAINING	\$0	\$0	\$0	\$0	\$0	\$0
2 GRADUATE MEDICAL EDUCATION	0	0	0	0	0	0
2 Cancer Center Operations						
1 CANCER CENTER OPERATIONS	0	0	0	0	0	0
3 Operations - Staff Benefits						
1 STAFF GROUP INSURANCE PREMIUMS	26,760	27,295	0	0	26,760	27,295
4 Operations - Statutory Funds						
1 TEXAS PUBLIC EDUCATION GRANTS	110,946	113,720	0	0	110,946	113,720
TOTAL, GOAL 1	\$137,706	\$141,015	\$0	\$0	\$137,706	\$141,015
2 Provide Research Support						
1 Research Activities						
1 RESEARCH ENHANCEMENT	0	0	0	0	0	0
TOTAL, GOAL 2	\$0	\$0	\$0	\$0	\$0	\$0
3 Provide Infrastructure Support						
1 Operations and Maintenance						
1 E&G SPACE SUPPORT	0	0	0	0	0	0
2 Infrastructure Support						
1 CCAP REVENUE BONDS	17,419,549	17,397,199	0	0	17,419,549	17,397,199
TOTAL, GOAL 3	\$17,419,549	\$17,397,199	\$0	\$0	\$17,419,549	\$17,397,199

2.F. Summary of Total Request by Strategy
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE : 7/21/2022
TIME : 1:50:42PM

Agency code: 506	Agency name: The University of Texas M.D. Anderson Cancer Center					
Goal/Objective/STRATEGY	Base 2024	Base 2025	Exceptional 2024	Exceptional 2025	Total Request 2024	Total Request 2025
5 Provide Non-formula Support						
1 <i>Research</i>						
1 CORD BLOOD AND CELLULAR THERAPY	\$1,389,551	\$1,389,550	\$610,449	\$610,450	\$2,000,000	\$2,000,000
2 BREAST CANCER RESEARCH PROGRAM	1,444,000	1,444,000	556,000	556,000	2,000,000	2,000,000
2 <i>Institutional</i>						
1 INSTITUTIONAL ENHANCEMENT	2,164	2,164	0	0	2,164	2,164
TOTAL, GOAL 5	\$2,835,715	\$2,835,714	\$1,166,449	\$1,166,450	\$4,002,164	\$4,002,164
7 Tobacco Funds						
1 <i>Tobacco Earnings for Research</i>						
1 TOBACCO EARNINGS - UT MD ANDERSON	6,890,000	6,890,000	0	0	6,890,000	6,890,000
2 TOBACCO - PERMANENT HEALTH FUND	2,561,891	2,561,891	0	0	2,561,891	2,561,891
TOTAL, GOAL 7	\$9,451,891	\$9,451,891	\$0	\$0	\$9,451,891	\$9,451,891
TOTAL, AGENCY STRATEGY REQUEST	\$29,844,861	\$29,825,819	\$1,166,449	\$1,166,450	\$31,011,310	\$30,992,269
TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST						
GRAND TOTAL, AGENCY REQUEST	\$29,844,861	\$29,825,819	\$1,166,449	\$1,166,450	\$31,011,310	\$30,992,269

2.F. Summary of Total Request by Strategy
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE : 7/21/2022
TIME : 1:50:42PM

Agency code: 506		Agency name: The University of Texas M.D. Anderson Cancer Center					
Goal/Objective/STRATEGY		Base 2024	Base 2025	Exceptional 2024	Exceptional 2025	Total Request 2024	Total Request 2025
General Revenue Funds:							
1	General Revenue Fund	\$20,253,100	\$20,230,749	\$1,166,449	\$1,166,450	\$21,419,549	\$21,397,199
		\$20,253,100	\$20,230,749	\$1,166,449	\$1,166,450	\$21,419,549	\$21,397,199
General Revenue Dedicated Funds:							
704	Est Bd Authorized Tuition Inc	0	0	0	0	0	0
770	Est. Other Educational & General	137,706	141,015	0	0	137,706	141,015
		\$137,706	\$141,015	\$0	\$0	\$137,706	\$141,015
Federal Funds:							
325	Coronavirus Relief Fund	0	0	0	0	0	0
		\$0	\$0	\$0	\$0	\$0	\$0
Other Funds:							
802	Lic Plate Trust Fund No. 0802, est	2,164	2,164	0	0	2,164	2,164
810	Perm Health Fund Higher Ed, est	2,561,891	2,561,891	0	0	2,561,891	2,561,891
812	Perm Endow FD UTMD AND, estimated	6,890,000	6,890,000	0	0	6,890,000	6,890,000
		\$9,454,055	\$9,454,055	\$0	\$0	\$9,454,055	\$9,454,055
TOTAL, METHOD OF FINANCING		\$29,844,861	\$29,825,819	\$1,166,449	\$1,166,450	\$31,011,310	\$30,992,269
FULL TIME EQUIVALENT POSITIONS		617.1	617.1	0.0	0.0	617.1	617.1

2.G. Summary of Total Request Objective Outcomes
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation system of Texas (ABEST)

Date : 7/21/2022

Time: 1:50:42PM

Agency code: **506**

Agency name: **The University of Texas M.D. Anderson Cancer Center**

Goal/ Objective / Outcome

		BL 2024	BL 2025	Excp 2024	Excp 2025	Total Request 2024	Total Request 2025
1	Provide Instructional and Operations Support						
1	<i>Instructional Programs</i>						
KEY	14 Percent Allied Health Grads Passing Certif/Licensure Exam First Try						
		90.00%	90.00%			90.00%	90.00%
KEY	15 Percent Allied Health Graduates Licensed or Certified in Texas						
		100.00%	100.00%			100.00%	100.00%
2	<i>Cancer Center Operations</i>						
KEY	1 Percent of Medical Residency Completers Practicing in Texas						
		33.00%	33.00%			33.00%	33.00%
KEY	2 Total Uncompensated Care Provided by Faculty						
		91,664,661.00	91,664,661.00			91,664,661.00	91,664,661.00
KEY	4 Administrative (Instit Support) Cost As % of Total Expenditures						
		3.50%	3.50%			3.50%	3.50%
KEY	5 Total Uncompensated Care Provided in State-owned Facilities						
		222,409,256.00	222,409,256.00			222,409,256.00	222,409,256.00
2	Provide Research Support						
1	<i>Research Activities</i>						
KEY	1 Total External Research Expenditures						
		657,498,369.00	667,360,845.00			657,498,369.00	667,360,845.00

2.G. Summary of Total Request Objective Outcomes
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation system of Texas (ABEST)

Date : 7/21/2022
Time: 1:50:42PM

Agency code: **506** Agency name: **The University of Texas M.D. Anderson Cancer Center**

Goal/ Objective / Outcome

	BL 2024	BL 2025	Excp 2024	Excp 2025	Total Request 2024	Total Request 2025
2 External Research Expends As % of State Appropriations for Research						
	4,530.62%	4,598.58%			4,530.62%	4,598.58%

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 1 Instructional Programs
STRATEGY: 1 Allied Health Professions Training

Service Categories:

Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
Efficiency Measures:						
KEY 1	Avg Cost of Resident Undergraduate Tuition and Fees for 15 Sch	2,012.00	2,085.00	2,163.00	2,163.00	2,163.00
Explanatory/Input Measures:						
KEY 1	Minority Admissions As % of Total First-Year Admissions (All Schools)	35.20 %	35.00 %	35.00 %	35.00 %	35.00 %
KEY 4	Average Financial Aid Award per Full-Time Student	11,846.00	11,846.00	11,846.00	11,846.00	11,846.00
KEY 5	Percent of Full-Time Students Receiving Financial Aid	72.00 %	72.00 %	72.00 %	72.00 %	72.00 %
Objects of Expense:						
1001	SALARIES AND WAGES	\$1,031,477	\$1,159,586	\$1,159,586	\$0	\$0
1005	FACULTY SALARIES	\$1,799,614	\$1,643,592	\$1,643,592	\$0	\$0
2001	PROFESSIONAL FEES AND SERVICES	\$105,411	\$3,715	\$3,715	\$0	\$0
2003	CONSUMABLE SUPPLIES	\$291,885	\$283,977	\$283,977	\$0	\$0
2007	RENT - MACHINE AND OTHER	\$8,085	\$405	\$405	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$86,970	\$169,472	\$169,472	\$0	\$0
5000	CAPITAL EXPENDITURES	\$195,375	\$103,656	\$103,656	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$3,518,817	\$3,364,403	\$3,364,403	\$0	\$0

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 1 Instructional Programs
STRATEGY: 1 Allied Health Professions Training

Service Categories:

Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
Method of Financing:						
1	General Revenue Fund	\$3,427,960	\$3,204,403	\$3,204,403	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$3,427,960	\$3,204,403	\$3,204,403	\$0	\$0
Method of Financing:						
704	Est Bd Authorized Tuition Inc	\$86,438	\$79,899	\$81,896	\$0	\$0
770	Est. Other Educational & General	\$4,419	\$80,101	\$78,104	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)		\$90,857	\$160,000	\$160,000	\$0	\$0
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$0	\$0
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$3,518,817	\$3,364,403	\$3,364,403	\$0	\$0
FULL TIME EQUIVALENT POSITIONS:		10.0	9.4	9.0	9.0	9.0

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Instruction and Operations Formula provides funding for faculty salaries, departmental operating expense, library, instructional administration, student services and institutional support. The formula for this strategy is based on weighted allied health student full time equivalent. The rate per weighted student headcount or full-time equivalent is established by the Legislature each biennium.

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 1 Instructional Programs

Service Categories:

STRATEGY: 1 Allied Health Professions Training

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
------	-------------	----------	----------	----------	------------------------	------------------------

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

The clinical experience offered by the School of Health Professions prepares students to enter the job market with a wide range of skills and knowledge, so that they can compete for highly sought-after jobs within health care organizations.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$6,728,806	\$0	\$(6,728,806)	\$(6,728,806)	Formula funded strategies are not requested in 2024-25
			\$(6,728,806)	Total of Explanation of Biennial Change

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 1 Instructional Programs
STRATEGY: 2 Graduate Medical Education

Service Categories:

Service: 19 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
Output Measures:						
KEY 1	Total Number of MD or DO Residents	146.00	150.00	150.00	150.00	150.00
Explanatory/Input Measures:						
KEY 1	Minority MD or DO Residents as a Percent of Total MD or DO Residents	16.44 %	12.00 %	12.00 %	12.00 %	12.00 %
Objects of Expense:						
1001	SALARIES AND WAGES	\$198,278	\$185,166	\$185,166	\$0	\$0
1005	FACULTY SALARIES	\$679,294	\$704,346	\$704,346	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$877,572	\$889,512	\$889,512	\$0	\$0
Method of Financing:						
1	General Revenue Fund	\$877,572	\$889,512	\$889,512	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$877,572	\$889,512	\$889,512	\$0	\$0
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$0	\$0
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$877,572	\$889,512	\$889,512	\$0	\$0
FULL TIME EQUIVALENT POSITIONS:		3.1	3.0	2.9	2.9	2.9

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 1 Instructional Programs

Service Categories:

STRATEGY: 2 Graduate Medical Education

Service: 19

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	(1) BL 2024	(1) BL 2025
------	-------------	----------	----------	----------	----------------	----------------

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Graduate Medical Education (GME) formula allocates funding based on the number of medical residents in accredited programs. These funds shall be used to increase the number of resident slots in the State of Texas as well as faculty costs relating to GME.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Successful GME programs require adequate resources to retain and recruit talented faculty and support staff, provide state-of-the-art facilities and maintain quality training programs. MDACC is committed to enhancing and identifying new sources of funding for these critical elements of its instruction mission.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$1,779,024	\$0	\$(1,779,024)	\$(1,779,024)	Formula funded strategies are not requested in 2024-25
			\$(1,779,024)	Total of Explanation of Biennial Change

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 2 Cancer Center Operations
STRATEGY: 1 Cancer Center Operations

Service Categories:

Service: 22 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
Efficiency Measures:						
2	Net Revenue Per Equivalent Patient Day	6,204.17	6,550.21	6,749.61	6,749.61	6,749.61
Objects of Expense:						
1001	SALARIES AND WAGES	\$138,489,709	\$136,174,943	\$136,174,943	\$0	\$0
1005	FACULTY SALARIES	\$1,918,281	\$4,233,047	\$4,233,047	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$140,407,990	\$140,407,990	\$140,407,990	\$0	\$0
Method of Financing:						
1	General Revenue Fund	\$40,790,362	\$140,407,990	\$140,407,990	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$40,790,362	\$140,407,990	\$140,407,990	\$0	\$0
Method of Financing:						
325	Coronavirus Relief Fund					
	21.019.119 COV19 Coronavirus Relief Fund	\$99,617,628	\$0	\$0	\$0	\$0
CFDA Subtotal, Fund	325	\$99,617,628	\$0	\$0	\$0	\$0
SUBTOTAL, MOF (FEDERAL FUNDS)		\$99,617,628	\$0	\$0	\$0	\$0

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 2 Cancer Center Operations

Service Categories:

STRATEGY: 1 Cancer Center Operations

Service: 22

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$0	\$0
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$140,407,990	\$140,407,990	\$140,407,990	\$0	\$0
FULL TIME EQUIVALENT POSITIONS:		498.5	468.5	450.4	450.4	450.4

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Cancer Center Operations Formula provides funding for faculty salaries, departmental operating expense, and institutional support. The formula for this strategy is based on the total number of Texas cancer patients served at The University of Texas M. D. Anderson Cancer Center. The rate per Texas cancer patient served is established by the Legislature each biennium. The amount of growth in total funding from one biennium to another may not exceed the average growth in funding for Health Related Institutions in the Instruction and Operations formula for the current biennium.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Efficient patient care programs require adequate resources to recruit and retain talented faculty and support staff and provide state-of-the-art facilities.

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 2 Cancer Center Operations

Service Categories:

STRATEGY: 1 Cancer Center Operations

Service: 22

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	(1) BL 2024	(1) BL 2025
------	-------------	----------	----------	----------	----------------	----------------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL CHANGE	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2022 + Bud 2023)	Baseline Request (BL 2024 + BL 2025)		\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$280,815,980	\$0	\$(280,815,980)	\$(280,815,980)	Formula funded strategies are not requested in 2024-25
			<u>\$(280,815,980)</u>	Total of Explanation of Biennial Change

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 3 Operations - Staff Benefits
STRATEGY: 1 Staff Group Insurance Premiums

Service Categories:

Service: 06 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
1002	OTHER PERSONNEL COSTS	\$26,725	\$26,936	\$26,235	\$26,760	\$27,295
TOTAL, OBJECT OF EXPENSE		\$26,725	\$26,936	\$26,235	\$26,760	\$27,295
Method of Financing:						
770	Est. Other Educational & General	\$26,725	\$26,936	\$26,235	\$26,760	\$27,295
SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)		\$26,725	\$26,936	\$26,235	\$26,760	\$27,295
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$26,760	\$27,295
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$26,725	\$26,936	\$26,235	\$26,760	\$27,295

FULL TIME EQUIVALENT POSITIONS:

STRATEGY DESCRIPTION AND JUSTIFICATION:

This strategy is to provide proportional share of staff group insurance premiums paid from Other Educational and General funds.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Staff Group Insurance Premium rates are set through U. T. System.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 3 Operations - Staff Benefits

Service Categories:

STRATEGY: 1 Staff Group Insurance Premiums

Service: 06

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$53,171	\$54,055	\$884	\$884	Driven by estimated changes in benefit proportionality and group insurance counts.
			\$884	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support
OBJECTIVE: 4 Operations - Statutory Funds
STRATEGY: 1 Texas Public Education Grants

Service Categories:

Service: 20 Income: A.1 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
4000	GRANTS	\$95,986	\$105,600	\$108,240	\$110,946	\$113,720
TOTAL, OBJECT OF EXPENSE		\$95,986	\$105,600	\$108,240	\$110,946	\$113,720
Method of Financing:						
770	Est. Other Educational & General	\$95,986	\$105,600	\$108,240	\$110,946	\$113,720
SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)		\$95,986	\$105,600	\$108,240	\$110,946	\$113,720
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$110,946	\$113,720
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$95,986	\$105,600	\$108,240	\$110,946	\$113,720

FULL TIME EQUIVALENT POSITIONS:

STRATEGY DESCRIPTION AND JUSTIFICATION:

This strategy represents tuition set aside for the Texas Public Education Grants program as required by Section 56.033 of the Texas Education Code.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 1 Provide Instructional and Operations Support

OBJECTIVE: 4 Operations - Statutory Funds

Service Categories:

STRATEGY: 1 Texas Public Education Grants

Service: 20

Income: A.1

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$213,840	\$224,666	\$10,826	\$10,826	Driven by projected increases in enrollment for the 2024-25 biennium
			\$10,826	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 2 Provide Research Support
OBJECTIVE: 1 Research Activities
STRATEGY: 1 Research Enhancement

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
Objects of Expense:						
1001	SALARIES AND WAGES	\$7,599,857	\$8,325,036	\$8,325,036	\$0	\$0
1005	FACULTY SALARIES	\$3,929,781	\$4,381,752	\$4,381,752	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$11,529,638	\$12,706,788	\$12,706,788	\$0	\$0
Method of Financing:						
1	General Revenue Fund	\$11,529,638	\$12,706,788	\$12,706,788	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$11,529,638	\$12,706,788	\$12,706,788	\$0	\$0
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$0	\$0
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$11,529,638	\$12,706,788	\$12,706,788	\$0	\$0
FULL TIME EQUIVALENT POSITIONS:		40.9	42.4	40.8	40.8	40.8

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Research Enhancement formula allocates a base amount of \$1,412,500 to each institution in addition to a percentage of the total research expenditures as reported to the Texas Higher Education Coordinating Board. The percent of additional funding above the base is established by the Legislature each biennium. These funds are used to support the research activities of the institution.

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 2 Provide Research Support

OBJECTIVE: 1 Research Activities

STRATEGY: 1 Research Enhancement

Service Categories:

Service: 21

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
------	-------------	----------	----------	----------	------------------------	------------------------

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Successful research programs require adequate resources to recruit and retain talented faculty and support staff, provide state-of-the-art facilities and maintain quality training programs. MDACC is committed to enhancing and identifying new sources of funding for these critical elements of its research mission.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$25,413,576	\$0	\$(25,413,576)	\$(25,413,576)	Formula funded strategies are not requested in 2024-25
			\$(25,413,576)	Total of Explanation of Biennial Change

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 3 Provide Infrastructure Support
OBJECTIVE: 1 Operations and Maintenance
STRATEGY: 1 E&G Space Support

Service Categories:

Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	(1) BL 2024	(1) BL 2025
Objects of Expense:						
1001	SALARIES AND WAGES	\$28,693,380	\$30,749,463	\$30,749,463	\$0	\$0
2003	CONSUMABLE SUPPLIES	\$2,323	\$2,189	\$2,189	\$0	\$0
2004	UTILITIES	\$3,208,922	\$3,840,603	\$3,852,046	\$0	\$0
2009	OTHER OPERATING EXPENSE	\$152,683	\$983	\$9,733	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$32,057,308	\$34,593,238	\$34,613,431	\$0	\$0
Method of Financing:						
1	General Revenue Fund	\$31,539,966	\$34,072,172	\$34,072,172	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$31,539,966	\$34,072,172	\$34,072,172	\$0	\$0
Method of Financing:						
770	Est. Other Educational & General	\$517,342	\$521,066	\$541,259	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS - DEDICATED)		\$517,342	\$521,066	\$541,259	\$0	\$0

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 3 Provide Infrastructure Support
OBJECTIVE: 1 Operations and Maintenance
STRATEGY: 1 E&G Space Support

Service Categories:

Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$0	\$0
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$32,057,308	\$34,593,238	\$34,613,431	\$0	\$0
FULL TIME EQUIVALENT POSITIONS:		101.9	102.5	98.7	98.7	98.7

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Infrastructure Support formula distributes funding associated with plant support and utilities. This formula is driven by the predicted square feet for health related institutions produced by the Texas Higher Education Coordinating Board's Space Projection Model.

Because the Space Projection Model does not account for hospital space, separate infrastructure funding for hospital space at the University of Texas M. D. Anderson Cancer Center shall be included in the total funding for the Cancer Center Operations formula.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Continuing expansion of MDACC to meet patient care and research demands may impact the strategy. Conversion of obsolete clinic and laboratory areas to provide adequate office space for MDACC faculty and staff may also affect the strategy.

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 3 Provide Infrastructure Support
OBJECTIVE: 1 Operations and Maintenance
STRATEGY: 1 E&G Space Support

Service Categories:

Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024 ⁽¹⁾	BL 2025 ⁽¹⁾
------	-------------	----------	----------	----------	------------------------	------------------------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		BIENNIAL CHANGE	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
Base Spending (Est 2022 + Bud 2023)	Baseline Request (BL 2024 + BL 2025)		\$ Amount	Explanation(s) of Amount (must specify MOFs and FTEs)
\$69,206,669	\$0	\$(69,206,669)	\$(69,206,669)	Formula funded strategies are not requested in 2024-25
			\$(69,206,669)	Total of Explanation of Biennial Change

(1) - Formula funded strategies are not requested in 2024-25 because amounts are not determined by institutions.

506 The University of Texas M.D. Anderson Cancer Center

GOAL:	3	Provide Infrastructure Support	
OBJECTIVE:	2	Infrastructure Support	Service Categories:
STRATEGY:	1	Capital Construction Assistance Projects Revenue Bond	Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
2008	DEBT SERVICE	\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
TOTAL, OBJECT OF EXPENSE		\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
Method of Financing:						
1	General Revenue Fund	\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$17,419,549	\$17,397,199
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$11,327,350	\$11,327,350	\$11,327,650	\$17,419,549	\$17,397,199
FULL TIME EQUIVALENT POSITIONS:						
STRATEGY DESCRIPTION AND JUSTIFICATION:						

506 The University of Texas M.D. Anderson Cancer Center

GOAL:	3	Provide Infrastructure Support	
OBJECTIVE:	2	Infrastructure Support	Service Categories:
STRATEGY:	1	Capital Construction Assistance Projects Revenue Bond	Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

The Capital Construction Assistance Projects (CCAP) Revenue Bond strategy is for the debt service on three CCAP bond projects.

The first project was funding of \$40,000,000 toward the Center for Targeted Therapy Research Building located on the UT Research Park. The facility provides space for the expanding experimental and molecular therapy research programs, which enable the discovery and development of novel drugs that block genetic and molecular changes to treat and prevent cancers.

The second project was funding of \$70,000,000 towards the Zayed building for personalized cancer care to accommodate the expanding research mission of M.D. Anderson and related programs focused on developing and advancing the most innovative therapeutics, diagnostics, early detection and prevention techniques to combat cancer.

The third project was funding of \$69,897,111 for construction of a life science research, innovation and discovery initiative facility. This new research building is a significant component of the TMC3 life science campus including collaboration of academia, medicine, and life science industry partners.

FY 2024 and FY 2025 debt service for outstanding CCAP revenue bonds has been requested based on actual CCAP debt service requirements for issued bonds and estimated amounts for Senate Bill 52 (87th Legislature, 3rd Called Session) authorizations.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 3 Provide Infrastructure Support
OBJECTIVE: 2 Infrastructure Support
STRATEGY: 1 Capital Construction Assistance Projects Revenue Bond

Service Categories:
Service: 10 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$22,655,000	\$34,816,748	\$12,161,748	\$12,161,748	Based on actual, known debt service requirements for 2024-25. Includes debt service for recently approved projects during the previous legislative session.
			\$12,161,748	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support

OBJECTIVE: 1 Research

Service Categories:

STRATEGY: 1 Cord Blood and Cellular Therapy Research Program

Service: 21

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
1001	SALARIES AND WAGES	\$280,625	\$408,657	\$408,657	\$408,657	\$408,657
1005	FACULTY SALARIES	\$1,620	\$12,761	\$12,761	\$12,761	\$12,761
2009	OTHER OPERATING EXPENSE	\$818,669	\$968,133	\$968,133	\$968,133	\$968,132
TOTAL, OBJECT OF EXPENSE		\$1,100,914	\$1,389,551	\$1,389,551	\$1,389,551	\$1,389,550
Method of Financing:						
1	General Revenue Fund	\$1,100,914	\$1,389,551	\$1,389,551	\$1,389,551	\$1,389,550
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$1,100,914	\$1,389,551	\$1,389,551	\$1,389,551	\$1,389,550
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$1,389,551	\$1,389,550
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$1,100,914	\$1,389,551	\$1,389,551	\$1,389,551	\$1,389,550
FULL TIME EQUIVALENT POSITIONS:		1.0	1.4	1.4	1.4	1.4
STRATEGY DESCRIPTION AND JUSTIFICATION:						

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support

OBJECTIVE: 1 Research

STRATEGY: 1 Cord Blood and Cellular Therapy Research Program

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

With approval from the LBB and Governor's office, non-formula item renamed from Research Support to Cord Blood & Cellular Therapy Research Program. General Revenue Funding from Institutional Enhancement was consolidated into this strategy for the 2022-2023 biennium.

Funding supports the UT MD Anderson Cord Blood Bank and Good Manufacturing Laboratory (GMP) with the development and management of critical research protocols for cord blood transplantation and other cellular therapies. Cord blood provides a source of stem cells for transplant for minority patients who often have no registered donors. MD Anderson serves an unmet need as 75% of the cord blood units in the bank are of Hispanic origin and the institution finds units for patients that otherwise would not have donors.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Additional information for this strategy is available in Schedule 9, Non formula Support.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>	<u>CHANGE</u>	<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$2,779,102	\$2,779,101	\$(1)	\$(1)	Based on GR limit
			\$(1)	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support
OBJECTIVE: 1 Research
STRATEGY: 2 Breast Cancer Research Program

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
1001	SALARIES AND WAGES	\$575,395	\$531,754	\$531,754	\$531,754	\$531,754
1002	OTHER PERSONNEL COSTS	\$9,727	\$9,391	\$9,391	\$9,391	\$9,391
1005	FACULTY SALARIES	\$308,631	\$300,876	\$300,876	\$300,876	\$300,876
2001	PROFESSIONAL FEES AND SERVICES	\$89,374	\$95,579	\$95,579	\$95,579	\$95,579
2003	CONSUMABLE SUPPLIES	\$38,543	\$83,619	\$83,619	\$83,619	\$83,619
2009	OTHER OPERATING EXPENSE	\$473,534	\$422,781	\$422,781	\$422,781	\$422,781
5000	CAPITAL EXPENDITURES	\$24,796	\$0	\$0	\$0	\$0
TOTAL, OBJECT OF EXPENSE		\$1,520,000	\$1,444,000	\$1,444,000	\$1,444,000	\$1,444,000
Method of Financing:						
1	General Revenue Fund	\$1,520,000	\$1,444,000	\$1,444,000	\$1,444,000	\$1,444,000
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$1,520,000	\$1,444,000	\$1,444,000	\$1,444,000	\$1,444,000
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$1,444,000	\$1,444,000
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$1,520,000	\$1,444,000	\$1,444,000	\$1,444,000	\$1,444,000
FULL TIME EQUIVALENT POSITIONS:		3.1	2.8	2.7	2.7	2.7

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support
OBJECTIVE: 1 Research
STRATEGY: 2 Breast Cancer Research Program

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Breast Cancer Research Program strategy funds programmatic research for Inflammatory Breast Cancer (IBC), a rare and often lethal type of breast cancer, which represents 10% of breast cancer mortality. Our mission is to eliminate IBC from Texas, USA, and the world. We want Texas to continue to be recognized as the preeminent worldwide leader of fighting this rare but deadly disease.

Since it was established in 2007, the "Morgan Welch Inflammatory Breast Cancer (IBC) Research Program and Clinic" at MD Anderson Cancer Center continues to lead the way in diagnosis, treatment, translational research, collaboration, and community education for this aggressive disease.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Additional information for this strategy is available in Schedule 9, Non formula support.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$2,888,000	\$2,888,000	\$0		
			\$0	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support
OBJECTIVE: 2 Institutional
STRATEGY: 1 Institutional Enhancement

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
1001	SALARIES AND WAGES	\$361,772	\$0	\$0	\$0	\$0
4000	GRANTS	\$0	\$4,397	\$4,664	\$2,164	\$2,164
TOTAL, OBJECT OF EXPENSE		\$361,772	\$4,397	\$4,664	\$2,164	\$2,164
Method of Financing:						
1	General Revenue Fund	\$361,772	\$0	\$0	\$0	\$0
SUBTOTAL, MOF (GENERAL REVENUE FUNDS)		\$361,772	\$0	\$0	\$0	\$0
Method of Financing:						
802	Lic Plate Trust Fund No. 0802, est	\$0	\$4,397	\$4,664	\$2,164	\$2,164
SUBTOTAL, MOF (OTHER FUNDS)		\$0	\$4,397	\$4,664	\$2,164	\$2,164
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$2,164	\$2,164
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$361,772	\$4,397	\$4,664	\$2,164	\$2,164
FULL TIME EQUIVALENT POSITIONS:		1.3	0.0	0.0	0.0	0.0

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 5 Provide Non-formula Support
OBJECTIVE: 2 Institutional
STRATEGY: 1 Institutional Enhancement

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

STRATEGY DESCRIPTION AND JUSTIFICATION:

With approval from the LBB and Governor's office, general revenue funding from the Institutional Enhancement strategy was consolidated into the Cord Blood & Cellular Therapy Research program for the 2022-23 biennium. Funding in this strategy beginning in FY 2022 will only include funds from the Texas Collegiate License Plate Trust Fund.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

Additional information for this strategy is available in Schedule 9, Non formula support.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$9,061	\$4,328	\$(4,733)	\$(4,733)	2022-2023 biennium includes estimated use of prior year balances related to license plate trust fund scholarships.
			<u>\$(4,733)</u>	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 7 Tobacco Funds
OBJECTIVE: 1 Tobacco Earnings for Research
STRATEGY: 1 Tobacco Earnings for The University of Texas MD Anderson Cancer Center

Service Categories:
Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
1001	SALARIES AND WAGES	\$3,500,371	\$2,554,731	\$2,554,731	\$2,230,372	\$2,230,372
1002	OTHER PERSONNEL COSTS	\$1,206,957	\$897,715	\$897,715	\$783,738	\$783,738
1005	FACULTY SALARIES	\$1,183,764	\$926,629	\$926,629	\$808,980	\$808,980
2009	OTHER OPERATING EXPENSE	\$2,786,179	\$3,975	\$1,206,778	\$1,053,561	\$1,053,561
5000	CAPITAL EXPENDITURES	\$0	\$1,850,500	\$2,306,147	\$2,013,349	\$2,013,349
TOTAL, OBJECT OF EXPENSE		\$8,677,271	\$6,233,550	\$7,892,000	\$6,890,000	\$6,890,000
Method of Financing:						
812	Perm Endow FD UTMD AND, estimated	\$8,677,271	\$6,233,550	\$7,892,000	\$6,890,000	\$6,890,000
SUBTOTAL, MOF (OTHER FUNDS)		\$8,677,271	\$6,233,550	\$7,892,000	\$6,890,000	\$6,890,000
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$6,890,000	\$6,890,000
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$8,677,271	\$6,233,550	\$7,892,000	\$6,890,000	\$6,890,000
FULL TIME EQUIVALENT POSITIONS:		16.6	11.6	11.2	11.2	11.2

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 7 Tobacco Funds

OBJECTIVE: 1 Tobacco Earnings for Research Service Categories:

STRATEGY: 1 Tobacco Earnings for The University of Texas MD Anderson Cancer Center Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

STRATEGY DESCRIPTION AND JUSTIFICATION:

Funding for this strategy is derived from annual distributions of Permanent Health Funds established Section 63.101 of the Texas Education Code. These are appropriated for research and other programs that are conducted by the institution and that benefit the public health.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

MDACC is committed to leveraging the tobacco funds to enhance and identify new sources of funding for these critical elements of its research mission.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$14,125,550	\$13,780,000	\$(345,550)	\$(345,550)	Prior biennium represented prior year balances, interest income and current year distributions.
			<u>\$(345,550)</u>	Total of Explanation of Biennial Change

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 7 Tobacco Funds
OBJECTIVE: 1 Tobacco Earnings for Research Service Categories:
STRATEGY: 2 Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810 Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
Objects of Expense:						
2001	PROFESSIONAL FEES AND SERVICES	\$410,357	\$312,576	\$312,576	\$196,734	\$196,734
2003	CONSUMABLE SUPPLIES	\$59,523	\$41,214	\$41,214	\$25,940	\$25,940
2004	UTILITIES	\$3,505	\$2,373	\$2,373	\$1,494	\$1,494
2005	TRAVEL	\$0	\$86	\$86	\$54	\$54
2007	RENT - MACHINE AND OTHER	\$636	\$127	\$127	\$80	\$80
2009	OTHER OPERATING EXPENSE	\$257,474	\$301,674	\$681,476	\$428,920	\$428,920
5000	CAPITAL EXPENDITURES	\$2,469,978	\$4,669,884	\$3,032,539	\$1,908,669	\$1,908,669
TOTAL, OBJECT OF EXPENSE		\$3,201,473	\$5,327,934	\$4,070,391	\$2,561,891	\$2,561,891
Method of Financing:						
810	Perm Health Fund Higher Ed, est	\$3,201,473	\$5,327,934	\$4,070,391	\$2,561,891	\$2,561,891
SUBTOTAL, MOF (OTHER FUNDS)		\$3,201,473	\$5,327,934	\$4,070,391	\$2,561,891	\$2,561,891
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$2,561,891	\$2,561,891
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$3,201,473	\$5,327,934	\$4,070,391	\$2,561,891	\$2,561,891
FULL TIME EQUIVALENT POSITIONS:						

506 The University of Texas M.D. Anderson Cancer Center

GOAL: 7 Tobacco Funds
OBJECTIVE: 1 Tobacco Earnings for Research Service Categories:
STRATEGY: 2 Tobacco Earnings from the Permanent Health Fund for Higher Ed. No. 810 Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2021	Est 2022	Bud 2023	BL 2024	BL 2025
------	-------------	----------	----------	----------	---------	---------

STRATEGY DESCRIPTION AND JUSTIFICATION:

This strategy includes the institution's allocation of the Permanent Health Fund for Higher Education. The purpose of these funds includes medical research, health education or treatment programs.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

MDACC is committed to leveraging the tobacco funds to enhance and identify new sources of funding for these critical elements of its research mission.

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2022 + Bud 2023)</u>	<u>Baseline Request (BL 2024 + BL 2025)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$9,398,325	\$5,123,782	\$(4,274,543)	\$(4,274,543)	Prior biennium represented prior year balances, interest income, and current year distributions.
			<u>\$(4,274,543)</u>	Total of Explanation of Biennial Change

SUMMARY TOTALS:

OBJECTS OF EXPENSE:	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819
METHODS OF FINANCE (INCLUDING RIDERS):				\$29,844,861	\$29,825,819
METHODS OF FINANCE (EXCLUDING RIDERS):	\$214,702,816	\$217,821,249	\$218,244,855	\$29,844,861	\$29,825,819
FULL TIME EQUIVALENT POSITIONS:	676.4	641.6	617.1	617.1	617.1

3.B. Rider Revisions and Additions Request

Agency Code: 506	Agency Name: The University of Texas M. D. Anderson Cancer Center	Prepared By: Tomas Guajardo	Date: August 2022	Request Level:
Current Rider Number	Page Number in 2020-21 GAA	Proposed Rider Language		
5	III-196	<p>5. Estimated Appropriation and Unexpended Balance. Included in the amounts appropriated above are: (1) estimated appropriations of amounts available for distribution or investment returns out of the Permanent Endowment Fund for The University of Texas M.D. Anderson Cancer Center No. 812 and (2) estimated appropriations of the institution's estimated allocation of amounts available for distribution out of the Permanent Health Fund for Higher Education No.810.</p> <p>a. Amounts available for distribution or investment returns in excess of the amounts estimated above are also appropriated to the institution. In the event that amounts available for distribution or investment returns are less than the amounts estimated above, this Act may not be construed as appropriating funds to make-up the difference.</p> <p>b. All balances of estimated appropriations from the Permanent Endowment Fund for The University of Texas M.D. Anderson Cancer Center No. 812 and of the institution's allocation from the amounts available for distribution out of the Permanent Health Fund for Higher Education No. 810, except for any General Revenue, at the close of the fiscal year ending August 31, 2024 2023, and the income to said fund during the fiscal years beginning September 1, 2024 2023, are hereby appropriated. Any unexpended appropriations made above as of August 31, 2022 2024, are hereby appropriated to the institution for the same purposes for fiscal year 2023 2025.</p> <p><i>M.D. Anderson requests that the dates in the rider be updated for the next biennium.</i></p>		
8	III-196	<p>8. Rare and Aggressive Breast Cancer Research Program. Of the amounts appropriated above in Strategy D.1.2, Breast Cancer Research Program, \$1,444,000 in fiscal year 2022 2024 and \$1,444,000 in fiscal year 2023 2025 in General Revenue is for the rare and aggressive breast cancer research program. Its efforts will contribute to improving the diagnostics in patients with breast cancer.</p> <p><i>M.D. Anderson requests that the dates in the rider be updated for the next biennium.</i></p>		

10	III-197	<p>10. Telemedicine Medical Services to Certain Cancer Patients Pilot Program. The University of Texas M.D. Anderson Cancer Center, in conjunction with the Texas Medical Board, shall develop and implement a pilot program authorizing a physician or other health care provider to prescribe, through a telemedicine medical service, drugs for pain management or supportive palliative care to a patient with a current or previous cancer diagnosis and to provide other telemedicine medical services to those patients. The University of Texas M.D. Anderson Cancer Center shall submit a report on their findings to the Texas Medical Board and to the Legislature. The report shall include the number of patients who receive pain management services or supportive palliative care through telemedicine medical services under the pilot program; an estimate of patient attendance rates during the two biennia preceding August 31, 2021, for scheduled in person visits compared to telemedicine medical service appointments for pain management services or supportive palliative care; an evaluation of and recommendations for improvements to the pilot program; and recommendations for the expansion of the pilot program.</p> <p><i>M.D. Anderson requests that the rider be deleted. The corresponding emergency rule that prompted the rider request was made permanent by the Texas Medical Board. The rider is no longer necessary. .</i></p>
----	---------	--

4.A. Exceptional Item Request Schedule
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:16PM

Agency code: 506 Agency name: The University of Texas M.D. Anderson Cancer Center

CODE	DESCRIPTION	Excp 2024	Excp 2025
------	-------------	-----------	-----------

Item Name:	Increases to Cord Blood and Cellular Therapy Research Program		
Item Priority:	1		
IT Component:	No		
Anticipated Out-year Costs:	Yes		
Involve Contracts > \$50,000:	No		
Includes Funding for the Following Strategy or Strategies:	05-01-01	Cord Blood and Cellular Therapy Research Program	

OBJECTS OF EXPENSE:

2009	OTHER OPERATING EXPENSE	610,449	610,450
TOTAL, OBJECT OF EXPENSE		\$610,449	\$610,450

METHOD OF FINANCING:

1	General Revenue Fund	610,449	610,450
TOTAL, METHOD OF FINANCING		\$610,449	\$610,450

DESCRIPTION / JUSTIFICATION:

Increases for the Cord Blood & Cellular Therapy Research Program.

EXTERNAL/INTERNAL FACTORS:

Lack of adequate funding will inhibit the ability to continue cutting-edge research which will allow us to treat cancer patients who have very few options. This includes those with refractory cancers for whom we are developing NK-CAR therapies. It also includes cancer patients with refractory GVHD which is often fatal without MSCs as well as cancer patients with chemotherapy induced heart and lung disease, all of whom may be cured with cord tissue derived MSCs. And cord blood natural killer cells (NK-CAR) which are producing very impressive responses in leukemia (CLL) and lymphoma with no toxicity and an overall response rate of 87%.

Year non-formula support item was first funded 2002. Additional information for this program is available in Schedule 9, Non formula support.

PCLS TRACKING KEY:

4.A. Exceptional Item Request Schedule
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:16PM

Agency code: 506

Agency name: The University of Texas M.D. Anderson Cancer Center

<u>CODE</u>	<u>DESCRIPTION</u>	<u>Excp 2024</u>	<u>Excp 2025</u>
-------------	--------------------	------------------	------------------

DESCRIPTION OF ANTICIPATED OUT-YEAR COSTS :

Requesting continuing funding

ESTIMATED ANTICIPATED OUT-YEAR COSTS FOR ITEM:

<u>2026</u>	<u>2027</u>	<u>2028</u>
\$610,449	\$610,450	\$610,449

4.A. Exceptional Item Request Schedule
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:16PM

Agency code: 506 Agency name: The University of Texas M.D. Anderson Cancer Center

CODE	DESCRIPTION	Excp 2024	Excp 2025
	Item Name: Increases to Breast Cancer Research (IBC)		
	Item Priority: 2		
	IT Component: No		
	Anticipated Out-year Costs: Yes		
	Involve Contracts > \$50,000: No		
	Includes Funding for the Following Strategy or Strategies: 05-01-02 Breast Cancer Research Program		
OBJECTS OF EXPENSE:			
2009	OTHER OPERATING EXPENSE	556,000	556,000
	TOTAL, OBJECT OF EXPENSE	\$556,000	\$556,000
METHOD OF FINANCING:			
1	General Revenue Fund	556,000	556,000
	TOTAL, METHOD OF FINANCING	\$556,000	\$556,000

DESCRIPTION / JUSTIFICATION:

This request fully restores the funding reduction from its original appropriations for the Inflammatory Breast Cancer (IBC) Research Program and Clinic

EXTERNAL/INTERNAL FACTORS:

IBC is an aggressive, often fatal, type of breast cancer commonly misdiagnosed. Through the Texas Legislature's investment, more patients with IBC are seen at MD Anderson than at any other center in the world. State funding provides for: continued development of the world's largest biorepository of tissue and serum samples from our IBC patients and partnerships with other centers around the world to expand the repository; accelerated research and development of new therapies, and ultimately improvement in the well-being of all women who suffer from this commonly diagnosed disease. Our program is able to sustain a world-class operation in large measure due to the funding support by the State of Texas. Unfortunately, IBC is considered an orphan disease, where there is a significant lack of funding through industry or extramural grant mechanisms. This coupled with inflation challenges our ability to expand program activities and the endeavors by our dedicated IBC team.

Year non-formula support item was first funded 2008. Additional information for this program is available in Schedule 9, Non formula support.

PCLS TRACKING KEY:

4.A. Exceptional Item Request Schedule
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:16PM

Agency code: 506 Agency name: The University of Texas M.D. Anderson Cancer Center

CODE	DESCRIPTION	Excp 2024	Excp 2025
------	-------------	-----------	-----------

DESCRIPTION OF ANTICIPATED OUT-YEAR COSTS :

Requesting continuing funding

ESTIMATED ANTICIPATED OUT-YEAR COSTS FOR ITEM:

2026	2027	2028
\$556,000	\$556,000	\$556,000

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
Code	Description				Excp 2024	Excp 2025
Item Name:		Increases to Cord Blood and Cellular Therapy Research Program				
Allocation to Strategy:		5-1-1	Cord Blood and Cellular Therapy Research Program			
OBJECTS OF EXPENSE:						
2009	OTHER OPERATING EXPENSE			610,449	610,450	
TOTAL, OBJECT OF EXPENSE				\$610,449	\$610,450	
METHOD OF FINANCING:						
1	General Revenue Fund			610,449	610,450	
TOTAL, METHOD OF FINANCING				\$610,449	\$610,450	

Agency code:	506	Agency name:	The University of Texas M.D. Anderson Cancer Center			
Code	Description				Excp 2024	Excp 2025
Item Name:		Increases to Breast Cancer Research (IBC)				
Allocation to Strategy:		5-1-2	Breast Cancer Research Program			
OBJECTS OF EXPENSE:						
2009	OTHER OPERATING EXPENSE			556,000	556,000	
TOTAL, OBJECT OF EXPENSE				\$556,000	\$556,000	
METHOD OF FINANCING:						
1	General Revenue Fund			556,000	556,000	
TOTAL, METHOD OF FINANCING				\$556,000	\$556,000	

4.C. Exceptional Items Strategy Request
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:17PM

Agency Code: **506** Agency name: **The University of Texas M.D. Anderson Cancer Center**

GOAL: 5 Provide Non-formula Support

OBJECTIVE: 1 Research

Service Categories:

STRATEGY: 1 Cord Blood and Cellular Therapy Research Program

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Excp 2024	Excp 2025
------	-------------	-----------	-----------

OBJECTS OF EXPENSE:

2009 OTHER OPERATING EXPENSE

610,449

610,450

Total, Objects of Expense

\$610,449

\$610,450

METHOD OF FINANCING:

1 General Revenue Fund

610,449

610,450

Total, Method of Finance

\$610,449

\$610,450

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

Increases to Cord Blood and Cellular Therapy Research Program

4.C. Exceptional Items Strategy Request
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 7/21/2022
TIME: 1:51:17PM

Agency Code: **506** Agency name: **The University of Texas M.D. Anderson Cancer Center**

GOAL: 5 Provide Non-formula Support

OBJECTIVE: 1 Research

Service Categories:

STRATEGY: 2 Breast Cancer Research Program

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Excp 2024	Excp 2025
------	-------------	-----------	-----------

OBJECTS OF EXPENSE:

2009	OTHER OPERATING EXPENSE	556,000	556,000
------	-------------------------	---------	---------

Total, Objects of Expense

\$556,000	\$556,000
------------------	------------------

METHOD OF FINANCING:

1	General Revenue Fund	556,000	556,000
---	----------------------	---------	---------

Total, Method of Finance

\$556,000	\$556,000
------------------	------------------

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

Increases to Breast Cancer Research (IBC)

6.A. Historically Underutilized Business Supporting Schedule
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 7/21/2022
Time: 1:51:17PM

Agency Code: 506 Agency: The University of Texas M.D. Anderson Cancer Center

COMPARISON TO STATEWIDE HUB PROCUREMENT GOALS

A. Fiscal Year - HUB Expenditure Information

Statewide HUB Goals	Procurement Category	% Goal	HUB Expenditures FY 2020			Total Expenditures		HUB Expenditures FY 2021			Total Expenditures	
			% Actual	Diff	Actual \$	FY 2020	% Goal	% Actual	Diff	Actual \$	FY 2021	
11.2%	Heavy Construction	0.0 %	0.0%	0.0%	\$0	\$0	0.0 %	0.0%	0.0%	\$0	\$0	
21.1%	Building Construction	9.0 %	3.4%	-5.6%	\$1,465,397	\$42,626,783	12.0 %	10.6%	-1.4%	\$7,317,974	\$69,089,337	
32.9%	Special Trade	12.0 %	10.0%	-2.0%	\$3,098,908	\$30,941,713	12.0 %	18.9%	6.9%	\$3,506,318	\$18,579,714	
23.7%	Professional Services	15.0 %	10.7%	-4.3%	\$1,688,339	\$15,784,547	18.0 %	10.5%	-7.5%	\$1,568,792	\$15,004,356	
26.0%	Other Services	20.0 %	12.1%	-7.9%	\$39,461,567	\$325,051,712	18.0 %	9.8%	-8.2%	\$30,227,467	\$308,028,239	
21.1%	Commodities	2.0 %	1.4%	-0.6%	\$17,362,045	\$1,285,723,881	1.8 %	1.9%	0.1%	\$26,695,715	\$1,382,663,255	
	Total Expenditures		3.7%		\$63,076,256	\$1,700,128,636		3.9%		\$69,316,266	\$1,793,364,901	

B. Assessment of Attainment of HUB Procurement Goals

Attainment:

FY20: Due to the worldwide pandemic, the agency fell below in BC, ST, PS, OS and CC category goals. FY21: The agency exceeded ST, and CC goals and fell below in BC, PS and OS category goals.

Applicability:

The "Heavy Construction" category was not applicable to agency operations in either FY2020 or FY2021.

Factors Affecting Attainment:

Extensive efforts were made in FY20:1) A 3 year contract with a HUB construction services team to identify and increase the capacity of HUBs initially in construction, 2) a MOU with The UT System HUB Program Office. Challenged faced the mid-FY20, due to the worldwide pandemic placed unprecedented hardship on financial resources; social distancing altered traditional business practices. Also, the HUB Construction Service Firm paused mid-FY20 due to Covid. Specialized pharmaceutical expenditures, which are a significant, consistently limit the institution's ability to meet HUB objectives given the lack of HUBs in this space. The agency's business as a dedicated cancer research and patient care center pose challenges to achieving HUB objectives. Purchases are restricted for clinical and research applications with limited (non-HUB) manufacturers or distributors. Additionally, many purchases are made through group purchasing organization to maximize the value of the funds entrusted to the agency. Specific areas of impact include specialized medical diagnostic equipment, pharmaceuticals and professional health services.

Agency Code: 506 Agency: The University of Texas M.D. Anderson Cancer Center

C. Good-Faith Efforts to Increase HUB Participation

Outreach Efforts and Mentor-Protégé Programs:

MD Anderson continues to conduct a positive and proactive HUB outreach, solicitation, and development program designed to create opportunities and promote HUB participation and utilization in all of its procurement processes. Normal distribution of current bid list to advocacy groups including Women's Contractor's Association, Greater Houston Black Chamber, Houston Minority Supplier Development Council, Women's Business Enterprise Alliance, and two local Procurement Assistance Centers for dissemination to their memberships to increase HUB bid participation. Active and regular participants in (virtual) HUB marketing and development events including EXPOs, and networking conferences.

HUB Program Staffing:

We currently have two staff members who support the HUB program by administering the operations, structures, reporting, and procedures. The team participates in economic opportunity forums to inform HUB firms regarding MD Anderson's Business opportunities and practices. Other additional significant HUB program efforts are increasing accountability with general contractors on larger construction projects and personalized HUB onboarding training materials for major construction firms. DEI executive steering committee established to integrate HUB program activities into other DEI institutional goals and programs.

Current and Future Good-Faith Efforts:

The calculation of MD Anderson's HUB goals are baseline/initiated from the State of Texas goals which are derived from a very broad array of general purpose goods and service. Additionally, MD Anderson has experienced little or no participation in its purchasing processes (i.e., request for proposals, an invitation to bid, etc.) from HUBs in procurement categories with no HUB capability and capacity. HUB team participates in prime contractor business reviews and short-list interviews ongoing in an effort to increase HUB participation. MD Anderson commits to a good faith effort to increase purchases from, and contract awards to, HUB firms consistent with the state's goals for HUB participation and overall economic development. Opportunities Forecasts assembled and distributed quarterly year to local advocacy group for distribution to their membership as well as provided at external networking events.

University of Texas M. D. Anderson Cancer Center
Estimated Funds Outside the Institution's Bill Pattern
2022-23 and 2024-25 Biennia

	2022-23 Biennium				2024-25 Biennium			
	<u>FY 2022 Revenue</u>	<u>FY 2023 Revenue</u>	<u>Biennium Total</u>	<u>Percent of Total</u>	<u>FY 2024 Revenue</u>	<u>FY 2025 Revenue</u>	<u>Biennium Total</u>	<u>Percent of Total</u>
APPROPRIATED SOURCES INSIDE THE BILL PATTERN								
State Appropriations (excluding HEGI & State Paid Fringes)	205,441,766	\$ 205,442,066	\$ 410,883,832		\$ 205,441,766	\$ 205,442,066	\$ 410,883,832	
Tuition and Fees (net of Discounts and Allowances)	869,839	864,914	1,734,753		882,212	899,857	1,782,069	
Endowment and Interest Income	9,140,683	9,451,891	18,592,574		9,640,929	9,833,747	19,474,676	
Sales and Services of Educational Activities (net)	-	-	-		-	-	-	
Sales and Services of Hospitals (net)	-	-	-		-	-	-	
Other Income	2,164	2,164	4,328		2,164	2,164	4,328	
Total	<u>215,454,452</u>	<u>215,761,035</u>	<u>431,215,487</u>	<u>3.4%</u>	<u>215,967,071</u>	<u>216,177,834</u>	<u>432,144,905</u>	<u>3.0%</u>
APPROPRIATED SOURCES OUTSIDE THE BILL PATTERN								
State Appropriations (HEGI & State Paid Fringes)	\$ 16,087,389	\$ 15,674,717	\$ 31,762,106		\$ 15,674,717	\$ 15,674,717	\$ 31,349,434	
Higher Education Assistance Funds	-	-	-		-	-	-	
Available University Fund	-	-	-		-	-	-	
Sales and Services of Hospital (net)	4,302,383,362	4,784,151,078	9,086,534,440		5,176,428,540	5,331,721,396	10,508,149,936	
Other Income	6,544,951	4,468,981	11,013,932		4,468,981	4,468,981	8,937,962	
Endowment and Interest Income	156,111,434	184,062,832	340,174,266		170,087,133	170,087,133	340,174,266	
State Grants and Contracts	51,687	56,474	108,161		56,474	56,474	112,948	
Total	<u>4,481,178,823</u>	<u>4,988,414,082</u>	<u>9,469,592,905</u>	<u>74.0%</u>	<u>5,366,715,845</u>	<u>5,522,008,701</u>	<u>10,888,724,546</u>	<u>75.0%</u>
NON-APPROPRIATED SOURCES								
Tuition and Fees (net of Discounts and Allowances)	1,049,549	1,106,996	2,156,545		1,162,346	1,220,463	2,382,809	
Federal Grants and Contracts	239,699,274	271,937,640	511,636,914		277,376,393	282,923,921	560,300,314	
State Grants and Contracts	45,721,776	46,361,091	92,082,867		47,288,313	48,234,079	95,522,392	
Local Government Grants and Contracts	242,492,984	270,403,864	512,896,848		275,811,941	281,328,180	557,140,121	
Private Gifts and Grants	103,967,352	125,000,000	228,967,352		127,500,000	130,050,000	257,550,000	
Endowment and Interest Income	148,888,566	185,937,168	334,825,734		189,655,911	193,449,029	383,104,940	
Sales and Services of Educational Activities (net)	2,000,000	1,500,000	3,500,000		1,530,000	1,560,600	3,090,600	
Sales and Services of Hospitals (net)	-	-	-		-	-	-	
Professional Fees (net)	431,664,830	465,908,164	897,572,994		504,110,401	519,233,713	1,023,344,114	
Auxiliary Enterprises (net)	30,800,054	36,891,131	67,691,185		37,628,954	38,381,533	76,010,487	
Other Income	118,223,135	120,531,019	238,754,154		122,941,639	125,400,472	248,342,111	
Total	<u>1,364,507,520</u>	<u>1,525,577,073</u>	<u>2,890,084,593</u>	<u>22.6%</u>	<u>1,585,005,898</u>	<u>1,621,781,990</u>	<u>3,206,787,888</u>	<u>22.1%</u>
TOTAL SOURCES	<u><u>\$ 6,061,140,795</u></u>	<u><u>\$ 6,729,752,190</u></u>	<u><u>\$ 12,790,892,985</u></u>	<u><u>100.0%</u></u>	<u><u>\$ 7,167,688,814</u></u>	<u><u>\$ 7,359,968,525</u></u>	<u><u>\$ 14,527,657,339</u></u>	<u><u>100.0%</u></u>

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center					
	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
Gross Tuition					
Gross Resident Tuition	571,375	638,650	654,616	670,981	687,756
Gross Non-Resident Tuition	429,531	459,199	470,679	482,446	494,507
Gross Tuition	1,000,906	1,097,849	1,125,295	1,153,427	1,182,263
Less: Resident Waivers and Exemptions (excludes Hazlewood)	0	0	0	0	0
Less: Non-Resident Waivers and Exemptions	(242,578)	(251,600)	(257,881)	(264,328)	(270,936)
Less: Hazlewood Exemptions	(2,350)	(2,500)	(2,563)	(2,627)	(2,693)
Less: Board Authorized Tuition Increases (TX. Educ. Code Ann. Sec. 54.008)	(86,438)	(79,899)	(81,896)	(83,943)	(86,042)
Less: Tuition increases charged to doctoral students with hours in excess of 100 (TX. Educ. Code Ann. Sec. 54.012)	0	0	0	0	0
Less: Tuition increases charged to undergraduate students with excessive hours above degree requirements. (TX. Educ. Code Ann. Sec. 61.0595)	0	0	0	0	0
Less: Tuition rebates for certain undergraduates (TX. Educ. Code Ann. Sec. 54.0065)	0	0	0	0	0
Plus: Tuition waived for Students 55 Years or Older (TX. Educ. Code Ann. Sec. 54.013)	0	0	0	0	0
Less: Tuition for repeated or excessive hours (TX. Educ. Code Ann. Sec. 54.014)	0	0	0	0	0
Plus: Tuition waived for Texas Grant Recipients (TX. Educ. Code Ann. Sec. 56.307)	0	0	0	0	0
Subtotal	669,540	763,850	782,955	802,529	822,592
Less: Transfer of funds for Texas Public Education Grants Program (Tex. Educ. Code Ann. Sec. 56c) and for Emergency Loans (Tex. Educ. Code Ann. Sec. 56d)	(95,986)	(105,600)	(108,240)	(110,946)	(113,720)
Less: Transfer of Funds (2%) for Physician/Dental Loans (Medical Schools)	0	0	0	0	0
Less: Statutory Tuition (Tx. Educ. Code Ann. Sec. 54.051) Set Aside for Doctoral Incentive Loan Repayment Program (Tx. Educ. Code Ann. Sec. 56.095)	0	0	0	0	0
Less: Other Authorized Deduction					
Net Tuition	573,554	658,250	674,715	691,583	708,872
Student Teaching Fees	0	0	0	0	0

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center					
	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
Special Course Fees	0	0	0	0	0
Laboratory Fees	0	0	0	0	0
Subtotal, Tuition and Fees (Formula Amounts for Health-Related Institutions)	573,554	658,250	674,715	691,583	708,872
OTHER INCOME					
Interest on General Funds:					
Local Funds in State Treasury	4,182	2,111	2,164	2,218	2,273
Funds in Local Depositories, e.g., local amounts	0	0	0	0	0
Other Income (Itemize)					
Subtotal, Other Income	4,182	2,111	2,164	2,218	2,273
Subtotal, Other Educational and General Income	577,736	660,361	676,879	693,801	711,145
Less: O.A.S.I. Applicable to Educational and General Local Funds Payrolls	(14,277)	(15,615)	(15,142)	(15,521)	(15,909)
Less: Teachers Retirement System and ORP Proportionality for Educational and General Funds	(14,973)	(16,643)	(16,139)	(17,068)	(17,580)
Less: Staff Group Insurance Premiums	(26,725)	(26,936)	(26,235)	(26,760)	(27,295)
Total, Other Educational and General Income (Formula Amounts for General Academic Institutions)	521,761	601,167	619,363	634,452	650,361
Reconciliation to Summary of Request for FY 2019-2021:					
Plus: Transfer of Funds for Texas Public Education Grants Program and Physician Loans	95,986	105,600	108,240	110,946	113,720
Plus: Transfer of Funds 2% for Physician/Dental Loans (Medical Schools)	0	0	0	0	0
Plus: Transfer of Funds for Cancellation of Student Loans of Physicians	0	0	0	0	0
Plus: Organized Activities	0	0	0	0	0
Plus: Staff Group Insurance Premiums	26,725	26,936	26,235	26,760	27,295
Plus: Board-authorized Tuition Income	86,438	79,899	81,896	83,943	86,042
Plus: Tuition Increases Charged to Doctoral Students with Hours in Excess of 100	0	0	0	0	0
Plus: Tuition Increases Charged to Undergraduate Students with Excessive Hours above Degree Requirements (TX. Educ. Code Ann. Sec. 61.0595)	0	0	0	0	0

Schedule 1A: Other Educational and General Income

7/21/2022 1:51:17PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center					
	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
Plus: Tuition rebates for certain undergraduates (TX Educ.Code Ann. Sec. 54.0065)	0	0	0	0	0
Plus: Tuition for repeated or excessive hours (TX. Educ. Code Ann. Sec. 54.014)	0	0	0	0	0
Less: Tuition Waived for Students 55 Years or Older	0	0	0	0	0
Less: Tuition Waived for Texas Grant Recipients	0	0	0	0	0
Total, Other Educational and General Income Reported on Summary of Request	730,910	813,602	835,734	856,101	877,418

Schedule 1B: Health-related Institutions Patient Related Income

7/21/2022 1:51:18PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
Health-related Institutions Patient Income:					
Medical Patient Income	4,302,383,362	4,784,151,078	5,176,428,540	5,331,721,396	5,491,673,038
Dental Patient Income	0	0	0	0	0
Interest on Funds in Local Depositories	221,576,941	195,811,523	184,062,832	188,664,403	193,381,013
Other (Itemize)					
Other Operating Revenue	8,067,590	2,263,018	4,468,981	4,580,706	4,695,224
Less: OASI Applicable to Other Funds Payroll	(97,486,215)	(105,480,865)	(107,921,707)	(110,619,749)	(113,385,243)
Less: Teachers Retirement System and ORP Proportionality for Other Funds	(102,236,658)	(112,427,165)	(115,028,744)	(121,645,581)	(125,294,947)
Less: Staff Group Insurance Premiums Applicable to Other Funds	(183,021,840)	(181,803,872)	(186,010,741)	(189,730,956)	(193,525,575)
Total, Health-related Institutions Patient Related Income	4,149,283,180	4,582,513,717	4,955,999,161	5,102,970,219	5,257,543,510
Health-related Institutions Patient-Related FTEs	14,675.4	15,089.5	15,900.5	16,726.4	17,593.6

Schedule 2: Selected Educational, General and Other Funds

7/21/2022 1:51:18PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
General Revenue Transfers					
Transfer from Coordinating Board for Texas College Work Study Program (2021, 2022, 2023)	0	0	0	0	0
Transfer from Coordinating Board for Professional Nursing Shortage Reduction Program	0	0	0	0	0
Transfer of GR Group Insurance Premium from Comptroller (UT and TAMU Components only)	7,009,502	6,854,961	6,854,961	6,854,961	6,854,961
Less: Transfer to Other Institutions	0	0	0	0	0
Less: Transfer to Department of Health, Disproportionate Share - State-Owned Hospitals (2021, 2022, 2023)	0	0	0	0	0
Other (Itemize)					
Hazlewood Reimbursement	173	173	0	0	0
Other: Fifth Year Accounting Scholarship	0	0	0	0	0
Texas Grants	82,975	49,087	54,310	54,310	54,310
B-on-Time Program	0	0	0	0	0
Texas Research Incentive Program	0	0	0	0	0
Less: Transfer to System Administration	0	0	0	0	0
GME Expansion	0	0	0	0	0
Subtotal, General Revenue Transfers	7,092,650	6,904,221	6,909,271	6,909,271	6,909,271
General Revenue HEF	0	0	0	0	0
Transfer from Available University Funds (UT, A&M and Prairie View A&M Only)	0	0	0	0	0
Other Additions (Itemize)					
Increase Capital Projects - Educational and General Funds	0	0	0	0	0
Transfer from Department of Health, Disproportionate Share - State-owned Hospitals (2021, 2022, 2023)	0	0	0	0	0
Transfers from Other Funds, e.g., Designated funds transferred for educational and general activities (Itemize)	0	0	0	0	0
Other (Itemize)					
Gross Designated Tuition (Sec. 54.0513)	686,126	706,709	727,911	749,748	772,240
Indirect Cost Recovery (Sec. 145.001(d))	114,220,525	117,647,141	121,176,555	124,811,851	128,556,207
Correctional Managed Care Contracts	0	0	0	0	0

Schedule 3B: Staff Group Insurance Data Elements (UT/A&M)

7/21/2022 1:51:18PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

	E&G Enrollment	GR Enrollment	GR-D/OEGI Enrollment	Total E&G (Check)	Local Non-E&G
GR & GR-D Percentages					
GR %	4.06%				
GR-D/Other %	95.94%				
Total Percentage	100.00%				
FULL TIME ACTIVES					
1a Employee Only	8,103	329	7,774	8,103	3,773
2a Employee and Children	2,704	110	2,594	2,704	922
3a Employee and Spouse	1,524	62	1,462	1,524	498
4a Employee and Family	3,097	126	2,971	3,097	1,078
5a Eligible, Opt Out	92	4	88	92	53
6a Eligible, Not Enrolled	70	3	67	70	37
Total for This Section	15,590	634	14,956	15,590	6,361
PART TIME ACTIVES					
1b Employee Only	1,042	42	1,000	1,042	552
2b Employee and Children	264	11	253	264	40
3b Employee and Spouse	133	5	128	133	63
4b Employee and Family	357	14	343	357	40
5b Eligible, Opt Out	269	11	258	269	121
6b Eligible, Not Enrolled	65	3	62	65	94
Total for This Section	2,130	86	2,044	2,130	910
Total Active Enrollment	17,720	720	17,000	17,720	7,271

506 The University of Texas M.D. Anderson Cancer Center

	E&G Enrollment	GR Enrollment	GR-D/OEGI Enrollment	Total E&G (Check)	Local Non-E&G
FULL TIME RETIREES by ERS					
1c Employee Only	3,032	123	2,909	3,032	1,179
2c Employee and Children	114	5	109	114	44
3c Employee and Spouse	1,168	47	1,121	1,168	454
4c Employee and Family	113	5	108	113	44
5c Eligible, Opt Out	24	1	23	24	9
6c Eligible, Not Enrolled	93	4	89	93	36
Total for This Section	4,544	185	4,359	4,544	1,766
PART TIME RETIREES by ERS					
1d Employee Only	0	0	0	0	0
2d Employee and Children	0	0	0	0	0
3d Employee and Spouse	0	0	0	0	0
4d Employee and Family	0	0	0	0	0
5d Eligible, Opt Out	0	0	0	0	0
6d Eligible, Not Enrolled	0	0	0	0	0
Total for This Section	0	0	0	0	0
Total Retirees Enrollment	4,544	185	4,359	4,544	1,766
TOTAL FULL TIME ENROLLMENT					
1e Employee Only	11,135	452	10,683	11,135	4,952
2e Employee and Children	2,818	115	2,703	2,818	966
3e Employee and Spouse	2,692	109	2,583	2,692	952
4e Employee and Family	3,210	131	3,079	3,210	1,122
5e Eligible, Opt Out	116	5	111	116	62
6e Eligible, Not Enrolled	163	7	156	163	73
Total for This Section	20,134	819	19,315	20,134	8,127

506 The University of Texas M.D. Anderson Cancer Center

	E&G Enrollment	GR Enrollment	GR-D/OEGI Enrollment	Total E&G (Check)	Local Non-E&G
TOTAL ENROLLMENT					
1f Employee Only	12,177	494	11,683	12,177	5,504
2f Employee and Children	3,082	126	2,956	3,082	1,006
3f Employee and Spouse	2,825	114	2,711	2,825	1,015
4f Employee and Family	3,567	145	3,422	3,567	1,162
5f Eligible, Opt Out	385	16	369	385	183
6f Eligible, Not Enrolled	228	10	218	228	167
Total for This Section	22,264	905	21,359	22,264	9,037

Schedule 4: Computation of OASI
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Agency 506 The University of Texas M.D. Anderson Cancer Center

Proportionality Percentage Based on Comptroller Accounting Policy Statement #011, Exhibit 2	2021		2022		2023		2024		2025	
	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>	<u>% to Total</u>	<u>Allocation of OASI</u>
General Revenue (% to Total)	4.3923	\$4,479,257	4.0644	\$4,469,456	3.7698	\$4,228,406	3.7698	\$4,334,116	3.7698	\$4,442,469
Other Educational and General Funds (% to Total)	0.0140	\$14,277	0.0142	\$15,615	0.0135	\$15,142	0.0135	\$15,521	0.0135	\$15,909
Health-Related Institutions Patient Income (% to Total)	95.5937	\$97,486,215	95.9214	\$105,480,865	96.2167	\$107,921,707	96.2167	\$110,619,749	96.2167	\$113,385,243
Grand Total, OASI (100%)	100.0000	\$101,979,749	100.0000	\$109,965,936	100.0000	\$112,165,255	100.0000	\$114,969,386	100.0000	\$117,843,621

Schedule 5: Calculation of Retirement Proportionality and ORP Differential

7/27/2022 2:59:15PM

88th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Description	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
Proportionality Amounts					
Gross Educational and General Payroll - Subject To TRS Retirement	1,208,522,521	1,293,205,989	1,277,849,168	1,316,184,643	1,355,670,182
Employer Contribution to TRS Retirement Programs	90,639,189	100,223,464	102,227,933	108,585,233	111,842,790
Gross Educational and General Payroll - Subject To ORP Retirement	247,120,755	257,335,297	262,482,002	270,356,463	278,467,156
Employer Contribution to ORP Retirement Programs	16,309,970	16,984,130	17,323,812	17,843,527	18,378,832
Proportionality Percentage					
General Revenue	4.3923 %	4.0644 %	3.7698 %	3.7698 %	3.7698 %
Other Educational and General Income	0.0140 %	0.0142 %	0.0135 %	0.0135 %	0.0135 %
Health-related Institutions Patient Income	95.5937 %	95.9214 %	96.2167 %	96.2167 %	96.2167 %
Proportional Contribution					
Other Educational and General Proportional Contribution (Other E&G percentage x Total Employer Contribution to Retirement Programs)	14,973	16,643	16,139	17,068	17,580
HRI Patient Income Proportional Contribution (HRI Patient Income percentage x Total Employer Contribution To Retirement Programs)	102,236,658	112,427,165	115,028,744	121,645,581	125,294,947
Differential					
Differential Percentage	1.9000 %	1.9000 %	1.9000 %	1.9000 %	1.9000 %
Gross Payroll Subject to Differential - Optional Retirement Program	71,140,823	74,081,373	75,563,001	77,829,891	80,164,787
Total Differential	1,351,676	1,407,546	1,435,697	1,478,768	1,523,131

Schedule 6: Constitutional Capital Funding
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

7/21/2022 1:51:19PM

506 The University of Texas M.D. Anderson Cancer Center					
Activity	Act 2021	Act 2022	Bud 2023	Est 2024	Est 2025
A. PUF Bond Proceeds Allocation	42,235,116	27,948,793	4,900,000	4,900,000	4,900,000
Project Allocation					
Library Acquisitions	0	0	0	0	0
Construction, Repairs and Renovations	37,334,989	25,390,388	2,400,000	2,400,000	2,400,000
Furnishings & Equipment	0	0	0	0	0
Computer Equipment & Infrastructure	0	0	0	0	0
Reserve for Future Consideration	0	0	0	0	0
Other (Itemize)					
PUF Bond Proceeds					
STARS & STARS+	4,900,127	2,558,405	2,500,000	2,500,000	2,500,000
B. HEF General Revenue Allocation	0	0	0	0	0
Project Allocation					
Library Acquisitions	0	0	0	0	0
Construction, Repairs and Renovations	0	0	0	0	0
Furnishings & Equipment	0	0	0	0	0
Computer Equipment & Infrastructure	0	0	0	0	0
Reserve for Future Consideration	0	0	0	0	0
HEF for Debt Service	0	0	0	0	0
Other (Itemize)					

Schedule 7: Personnel
88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 7/21/2022
Time: 1:51:19PM

Agency code: **506** Agency name: **UT MD Anderson Cancer Ctr**

	Actual	Actual	Budgeted	Estimated	Estimated
Part A.					
FTE Postions					
Directly Appropriated Funds (Bill Pattern)					
Educational and General Funds Faculty Employees	71.4	66.8	64.3	64.3	64.3
Educational and General Funds Non-Faculty Employees	605.0	574.8	552.8	552.8	552.8
Subtotal, Directly Appropriated Funds	676.4	641.6	617.1	617.1	617.1
Other Appropriated Funds					
Other (Itemize)	14,675.4	15,089.5	15,900.5	16,726.4	17,593.6
Subtotal, Other Appropriated Funds	14,675.4	15,089.5	15,900.5	16,726.4	17,593.6
Subtotal, All Appropriated	15,351.8	15,731.1	16,517.6	17,343.5	18,210.7
Non Appropriated Funds Employees	6,237.1	6,416.8	6,545.2	6,676.1	6,809.6
Subtotal, Other Funds & Non-Appropriated	6,237.1	6,416.8	6,545.2	6,676.1	6,809.6
GRAND TOTAL	21,588.9	22,147.9	23,062.8	24,019.6	25,020.3

Schedule 8B: Tuition Revenue Bond Issuance History

7/21/2022 1:51:19PM

88th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

506 The University of Texas M.D. Anderson Cancer Center

Authorization Date	Authorization Amount	Issuance Date	Issuance Amount	Authorized Amount Outstanding as of 08/31/2022	Proposed Issuance Date for Outstanding Authorization	Proposed Issuance Amount for Outstanding Authorization
2001	\$20,000,000	Jan 23 2003	\$20,000,000			
		Subtotal	\$20,000,000	\$0		
2003	\$20,000,000	Nov 4 2004	\$20,000,000			
		Subtotal	\$20,000,000	\$0		
2006	\$40,000,000	Feb 14 2008	\$1,036,000			
		Feb 15 2008	\$1,036,000			
		Aug 15 2008	\$1,417,000			
		Jan 6 2009	\$23,480,000			
		Feb 18 2009	\$1,520,000			
		Aug 3 2009	\$2,813,000			
		Mar 25 2010	\$8,698,000			
		Subtotal	\$40,000,000	\$0		
2015	\$70,000,000	May 10 2016	\$35,000,000			
		Jul 1 2016	\$15,000,000			
		Aug 22 2016	\$20,000,000			
		Subtotal	\$70,000,000	\$0		
2022	\$69,897,111				Sep 1 2022	\$69,897,111

Schedule 8C: CCAP Revenue Bond Debt Service Request by Project
88th Regular Session, Agency Submission

Agency Code: **506**

Agency Name: **The University of Texas M.D. Anderson Cancer Center**

Project Name	Authorization Year	Estimated Final Payment Date	Requested Amount 2024		Requested Amount 2025	
MDA Center for Targeted Therapy	2006	8/15/2024	\$	2,984,100.00	\$	-
MDA Building for Personalized Cancer Care	2015	8/15/2027	\$	8,341,500.00	\$	11,303,250.00
MDA Life Sciences Research,Innovation, and Disc	2022	8/15/2043	\$	6,093,949.00	\$	6,093,949.00
			\$	17,419,549.00	\$	17,397,199.00

506 The University of Texas M.D. Anderson Cancer Center

Cord Blood & Cellular Therapy Research Program

(1) Year Non-Formula Support Item First Funded:	2002
Year Non-Formula Support Item Established:	2002
Original Appropriation:	\$2,000,000

(2) Mission:

MD Anderson is the world leader in stem cell transplantation.

Funding currently supports the Cord Blood Bank and Good Manufacturing Laboratory (GMP) with the development and management of critical research protocols for cord blood transplantation and other cellular therapies, including rapid and exciting developments of chimeric antigen receptor (CAR) T cell therapy and CAR natural killer (NK) cell treatments for hematologic and solid tumors. These novel therapeutic approaches harness the body's own immune system to effectively fight cancers by killing abnormal cells. Cord blood provides a source of stem cells for transplant for minority patients who often have no registered donors. MD Anderson serves an unmet need as 75% of the cord blood units in the bank are of Hispanic origin and the institution finds units for patients that otherwise would not have donors.

(3) (a) Major Accomplishments to Date:

More than 30,000 cord blood units have been banked from five Houston Hospitals, and 1900 of those units have been transplanted into patients with no other therapeutic options. This has allowed the team to pioneer the use of novel cord blood derived cells for the treatment of cancer. Katy Rezvani MD PhD has developed cord blood natural killer cells genetically manipulated to express a chimeric antigen receptor (CAR) targeting CD19+ tumors. These NK-CAR cells are producing very impressive responses in leukemia (CLL) and lymphoma patients with no toxicity and an overall response rate of 87%. These results will likely change the standard of care for patients with otherwise fatal cancers, Elizabeth Shpall MD has developed strategies to expand cord blood hematopoietic cells in the laboratory to make the doses higher and thus the recovery faster when transplanted into patients. Developed a strategy called fucosylation to enhance the homing of cord blood to the bone marrow. Both have demonstrated more rapid recovery, making the transplants safer from infections and bleeding. The team is now combining expansion and fucosylation to try and make the recovery in cord blood patients even faster. Developing cord blood tissue derived mesenchymal stromal cells (MSCs) which can be life-saving when used to treat graft versus host disease. The development of investigational new drugs including T cells with response rates noted here CMV (94%), adenovirus (88%), BKV (88%), and COVID-19 (100%).

(3) (b) Major Accomplishments Expected During the Next 2 Years:

NK-CAR cells are being developed to target other cancers including acute myelogenous leukemia (AML), T cell leukemia and several solid tumors such as lung, pancreas and ovarian cancers. We are combining cord blood expansion and fucosylation to maximally enhance the recovery time of the cells when infused into patients which may allow us to do cord blood transplants as an outpatient. Cord blood tissue-derived MSCs and MSC-derived exosomes will be used for the eradication of GVHD, and to treat cancer patients who have developed cardiac injury from chemotherapy (anthracyclins) and cancer patients who have developed respiratory failure. Additionally, we are developing cord tissue MSCs, and MSC-derived exosomes as vehicles to deliver gene therapy to patients with otherwise fatal tumors such as glioblastoma and pancreatic cancer. We are developing an extremely novel approach to generate umbilical cord derived megakaryocytes (Megs) to make platelets which will address the global platelet shortages in Texas and the rest of the United States.

506 The University of Texas M.D. Anderson Cancer Center

(4) Funding Source Prior to Receiving Non-Formula Support Funding:

Prior to the budget reductions for FY 2012 - 2013, the MD Anderson Cord Blood Bank received funding from the legislature through the Texas Health and Human Services Commission.

(5) Formula Funding:

This item does not generate formula funding

(6) Category:

Research Support

(7) Transitional Funding:

N

(8) Non-General Revenue Sources of Funding:

General Revenue support is instrumental in advancing the field of cord blood transplantation and these funds have been leveraged to generate around \$12 million external funding for the program for the biennium.

(9) Impact of Not Funding:

Inability to continue the cutting edge research which will allow us to treat cancer patients who have very few options. This includes those with refractory cancers for whom we are developing NK-CAR therapies. It also includes cancer patients with refractory Graft vs Host Disease (GVHD) which is often fatal without MSCs as well as cancer patients with chemotherapy induced heart and lung disease, all of whom may be cured with cord tissue derived MSCs.

(10) Non-Formula Support Needed on Permanent Basis/Discontinuu

Permanent Basis

(11) Non-Formula Support Associated with Time Frame:

N/A

(12) Benchmarks:

N/A

(13) Performance Reviews:

The MD Anderson Cord Blood Bank is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), accepted into the networks of the National Marrow Donor Program (NMDP) and Health Resources and Services Administration (HRSA) and has recently received their FDA Biological license (one of 8 cord banks in the world who have received this license) which moving forward will be required to release clinical cords for transplant in the United States.

506 The University of Texas M.D. Anderson Cancer Center

Inflammatory Breast Cancer (IBC) Research Program

(1) Year Non-Formula Support Item First Funded:	2008
Year Non-Formula Support Item Established:	2008
Original Appropriation:	\$2,000,000

(2) Mission:

The Rare and Aggressive Breast Cancer Research Grant funds programmatic, multidisciplinary clinical and basic science research care for patients with Inflammatory Breast Cancer (IBC), a rare and most lethal disease with an incidence of 2-4% of breast cancers but unfortunately, representing 10% of breast cancer mortality. Since its inception in 2007, the "Morgan Welch Inflammatory Breast Cancer (IBC) Research Program and Clinic" at MD Anderson Cancer Center has led the way in IBC diagnosis, treatment, translational research, collaboration, and community education for this aggressive disease. Our goal is to prioritize and provide exceptional high-value care to the Texas community in Houston and beyond. We aim to eliminate IBC in the State of Texas, the USA, and internationally by continuing collaboration for innovation and breakthroughs. And we want to maintain and further elevate the recognition as the preeminent worldwide leader fighting this rare but deadly disease.

(3) (a) Major Accomplishments to Date:

1. Established IBC Multi-Team Clinic for personalizing care- Our team of specialists meets each IBC patient together in a rapid coordinated visit to provide IBC-specific trimodal care (chemotherapy/targeted therapy/immunotherapy, surgery, and radiation therapy), leading to improved local control and survival outcomes at the State of Texas and National Level.
2. Create and publish the IBC Clinical Practice Algorithm in the public domain to standardize IBC care in Texas and the USA - to create a standardized, consensus-based, comprehensive care for IBC
3. Increased IBC Clinical Research Portfolio- Clinical trials specifically addressing challenges we identified in IBC are essential to improve our patient outcomes.
4. Established IBC Connect Network to standardize IBC care and 'Team Science' collaborations to Innovate- IBC Connect.
5. Developed inter-institutional partnership for the IBC Registry database and 4 protocols. The clinical database and biorepository is the world's largest registry.
6. Generated funding for creating new IBC resources and grants to power pre-clinical research to innovate, collaborate and discover mechanisms to cure IBC.
7. Virtual IBC education seminar for physicians, advocates, and community- 175-200 members in attendance to discuss IBC care, collaborate, and innovate. Supported development of IBC Learning Academy, an advocacy training program led by IBC advocates to educate IBC in communities.

(3) (b) Major Accomplishments Expected During the Next 2 Years:

506 The University of Texas M.D. Anderson Cancer Center

1. Expand IBC Multi-Team Clinic care across Texas- Improved IBC local disease control and survival outcomes led to an annual patient volume increase from 17 to ~70 patients. Our goal is to reach 100-120 patients.
2. Expand IBC Clinical Research - We anticipate four (4) new IBC protocols (under development) in 2022, to be activated in the next 3-6 months and the first in the human multicenter study and trials with potential to prolong survival of Metastatic IBC patients without available therapies.
3. Expand IBC Research Collaborations- Expand neoadjuvant study in collaboration with Dana Farber Cancer Center (DFCI). Expand trials offered to Cancer network and IBC Connect partner institutions.
3. Create data alignment and resource-sharing opportunities to advance IBC team-science collaborations, co-develop protocols, and innovate to discover newer modalities of care – Create open access, IBC data platform to engage research experts in and outside Texas.
4. Continue to improve community outreach efforts and patient and physician education regarding IBC by providing educational information at the state , national, and international scale via IBC Connect, social media, and patient advocacy.
5. Continue to develop a pioneering roadmap to connect IBC expertise throughout the MDA and UT System across the State of Texas to enhance trial access and accelerate discovery to reduce the number of patients who suffer with IBC in Texas

(4) Funding Source Prior to Receiving Non-Formula Support Funding:

None

(5) Formula Funding:

This item does not generate formula funding

(6) Category:

Research Support

(7) Transitional Funding:

N

(8) Non-General Revenue Sources of Funding:

No alternate options at this time.

(9) Impact of Not Funding:

506 The University of Texas M.D. Anderson Cancer Center

Our program is able to function due to funding provided by the State of Texas, and a lack of will strongly impact our ability to sustain.

The consequence of not providing program funding would strongly impact all patients affected by IBC, the general public, state employees, and IBC Connect collaborators across fourteen (14) institutional sites. Additionally, in the absence of State funding, we would not be able to support the infrastructure to continue to educate and engage with institutional teams across multiple locations and the IBC community.

IBC has a median overall survival of only 4.75 years compared to 13.4 years for non-IBC patients. The median age of patients diagnosed with IBC is 5.25 years younger than that of non-IBC patients. Clinically, the program currently has ten (10) ongoing clinical trials with as many as 215 patients. These clinical studies are supported by an additional twenty-eight (28) laboratory studies with 869 patients and four (4) trials under development. If funding were discontinued, these critical patient-based studies would be detrimentally affected because there would not be infrastructure to support the studies. Further, we would fail to capitalize on our strategic positioning through diligent networking and relationship building across our regional and broader Texas network, missing the opportunity to impact IBC patients dramatically. These negative impacts will increase IBC-related mortality in Texas and the USA.

(10) Non-Formula Support Needed on Permanent Basis/Discontinuation

Permanent Basis

(11) Non-Formula Support Associated with Time Frame:

N/A

(12) Benchmarks:

N/A

(13) Performance Reviews:

1. Maintain the IBC Registry database, and compare local/regional control rates, survival outcomes, and quality of life outcomes over time. The data is currently aligned with DFCI for advanced team science research.
 2. Maintain and expand an IBC-specific clinic that is one of the largest in the world, which allows us to offer expertise and trial accrual not available elsewhere and facilitate a gathering of vital research information to translate into improved cure rates.
 3. Expand IBC partnership with institutions, focusing on the UT system and local organizations, to expand and further strengthen clinical and research collaborations.
 4. Expand partner site collaborations to increase available data in the IBC registry and patients enrolled at partner sites.
 5. Develop the first-ever IBC-specific PROs and gather data on quality-of-life outcomes that will improve over the next two years.
 6. We plan to publish five clinically oriented papers based on ongoing clinical trials that will change current practice within two years.
 7. We expect to publish five paradigm shift papers that will lead to novel diagnostics and treatments for patients with IBC within two years.
 8. Enroll > 50 IBC cases per year on protocols to identify better treatments, including a national trial to assess the microbiome in IBC patients for the first time.
 9. Train a minimum of two trainees per year, developing clinical or research expertise to contribute to the future of this disease.
-

506 The University of Texas M.D. Anderson Cancer Center

Institutional Enhancement

(1) Year Non-Formula Support Item First Funded: 2000
Year Non-Formula Support Item Established: 2000
Original Appropriation: \$1,000,000

(2) Mission:

Funding in the Institutional Enhancement strategy beginning in FY 2022 will only include funds from the Texas Collegiate License plate trust funds.

(3) (a) Major Accomplishments to Date:

Texas Collegiate License Plate scholarships for MD Anderson School of Health Professions students.

(3) (b) Major Accomplishments Expected During the Next 2 Years:

Texas Collegiate License Plate scholarships for MD Anderson School of Health Professions students.

(4) Funding Source Prior to Receiving Non-Formula Support Funding:

None

(5) Formula Funding:

This item does not generate formula funding

(6) Category:

Downward Expansion

(7) Transitional Funding:

N

(8) Non-General Revenue Sources of Funding:

Texas Collegiate License Plate Trust Fund

(9) Impact of Not Funding:

Will impact scholarships for MD Anderson School of Health Profession students.

(10) Non-Formula Support Needed on Permanent Basis/Discontinuation:

Permanent Basis

506 The University of Texas M.D. Anderson Cancer Center

(11) Non-Formula Support Associated with Time Frame:

N/A

(12) Benchmarks:

N/A

(13) Performance Reviews:

N/A
